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CHAPTER I: DRUG-TARGETING AND DRUG-RELOADING 
Abstract 
Although stents significantly reduce restenosis when compared with balloon angioplasty, 
restenosis rates in patients who receive stents are still 20% to 40% at 6 months12. Important is 
thereby the biocompatibility of the implant. Two categories of stent coatings may be 
distinguished: biocompatible coating to be less thrombogenic and inflammatory and drug-
eluting coating. Drug-eluting stents (DES) were developed to release drugs site-specific and 
hence to prevent restenosis. With the aid of DES, the restenosis rate decreased to 16% 13. 
However, after depletion the drug reservoir cannot be refilled. 
Drugs may be administered encapsulated in nanoparticles (NPs), but display a typical 
distribution in corpora depending on the NP's surface. Equipped with a cognition domain such 
as antibodies (so called "target-oriented" structure), the drug-carriers are able to "dock" to the 
targeting-moiety and release their drugs site-specifically. The advantage of drug-targeting is 
the increase of bioavailability and the decrease of side effects. Another aspect is the controlled 
drug-release over a specific time. The degradation rate of the NPs and thus of the drug-release 
is determined by its hydrophobic/hydrophilic ratio. If the degradation products are also 
biocompatible, it is called biodegradable. 
PLGA (Polyl(lactic-co-glycolic acid))-nanoparticles are commonly used as drug-carriers and 
have shown full biocompatibility both in vitro and in vivo studies23. Although PLGA-
biomaterials are generally biocompatible and non-toxic, several studies have reported 
inflammatory reactions11. This was utilised to immunise rabbits with PLGA-NP and produce 
antibodies against it (PLGA-Ab). The surface of PLGA-NPs acts now as recognition domain 
for the PLGA-Ab. PLGA-antibodies immobilised on implants specifically bind the 
nanoparticles and enrich them site-specific. 
PLGA-NPs are also biodegradable. By degradation to lactic and glycolic acid, the drugs are 
released; but also the conformation changes by and by. Thereby the binding to the PLGA-Ab 
weakens and the NPs dissociate again. New drug-carriers can now administered and reloading 
can take place. 
This principle of the combination of drug-targeting and drug-reloading has the advantage that 
new drugs can - adjusted to the specific needs of patients - site-specifically target the moiety 
with simultaneous increase of the bioavailability and decrease of side effects. 
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Abstract (German) 
Obwohl Stents signifikant das Risiko von Restenosis im Vergleich zur Ballon-Angioplastie 
herabsetzen, liegt die Restenosisrate bei Patienten mit Stents nach 6 Monaten noch immer bei 
20-40%. Entscheidend dabei ist die Biokompatibilität des Implantats. Zwei Kategorien von 
Stentbeschichtungen können unterschieden werden: biokompatible Beschichtung und drug-
eluting Beschichtung. Drug-eluting Stents (DES) wurden entwickelt, um Arzneimittel (drugs) 
ortsspezifisch freizusetzen und so einer Restenosis vorzubeugen. Mittels DES konnte die 
Restenosisrate auf 16% gesenkt werden. Sind die Arzneimittel jedoch aufgebraucht, können 
sie nicht wieder aufgefüllt werden. 
Drugs können eingeschlossen in Nanopartikel (NP) verabreicht werden, zeigen aber eine für 
sie typische Verteilung im Körper abhängig von der NP-Oberfläche. Ausgestattet mit einer 
Erkennungsdomäne wie z.B. Antikörper (man spricht von einer "ziel-orientierten" Struktur) 
können die drug-carrier an das Zielgewebe "andocken" und ortsspezifisch ihre Arzneimittel 
freisetzen. Der Vorteil von drug-targeting ist die Steigerung der Bioverfügbarkeit und 
Reduzierung der Nebeneffekte. Ein anderer Aspekt ist die kontrollierte Freisetzung der 
Arzneimittel über einen bestimmten Zeitraum. Der Abbau der NP und somit die 
Arzneimittelfreisetzung wird beeinflußt durch dessen hydrophoben zu hydrophilen Anteils. 
Sind auch dessen Abbauprodukte biokompatibel spricht man von biodegradabel. 
PLGA-Nanopartikel werden häufig als Arzneimittelträger genützt und sowohl in vitro als 
auch in vivo Studien haben deren vollständige Biokompatibilität gezeigt. Aber obwohl PLGA-
Materialien im Allgemeinen biokompatibel und nicht toxisch sind, haben einige Studien 
Entzündungsreaktionen aufgezeigt. Dies wurde ausgenutzt, um Kaninchen mit PLGA-NP zu 
immunisieren und so Antikörper (PLGA-Ak) gegen diese zu produzieren. Die Oberfläche von 
PLGA-NP agiert nun als Erkennungsdomäne. Immobilisiert man PLGA-Ak auf Implantaten, 
binden diese spezifisch die NP und es kommt zu einer ortsspezifischen Anreicherung.  
PLGA-NP sind auch biodegradabel. Bei der Degradation in Milch- und Glykolsäure werden 
die Wirkstoffe freigesetzt, aber auch die Konformation der NP ändert sich mit der Zeit. Dabei 
wird die Bindung an den Ak zunehmend schwächer und die NP dissoziieren. Neue drug-
carrier können verabreicht werden, ein Reloading kann durchgeführt werden. 
Diese Kombination von drug-targeting und drug-reloading hat den Vorteil, dass neue 
Arzneimittel – angepaßt an die spezifischen Bedürfnisse der Patienten – ortspezifisch an ihr 
Wirkungsfeld gelenkt werden können unter gleichzeitiger Steigerung der Bioverfügbarkeit 
und Reduzierung der Nebeneffekte. 
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1 Introduction 
1.1 Stents, Biomaterials and Biocompatible Coatings 
1.1.1 Stents – an Introduction 
Arteriosclerosis is a hardening of connective tissue caused by plaque deposition (calcification 
and adiposis) in blood vessel walls. Stenosis at coronary heart disease (CHD) leads to angina 
pectoris and myocardial infarction, which causes approximately half of all deaths of adults 
over age 60 in industrialized nations 1 . If medical attendance lowering blood pressure, 
cholesterol and triglyceride and applying anticoagulant is not efficient, the stenotic (narrowed) 
artery has to be widened by percutaneous transluminal (coronary) angioplasty (PTA, PTCA) 
by means of balloon dilation. In this procedure, a catheter having an inflatable balloon at its 
distal end is introduced into the coronary artery, the uninflated balloon is positioned at the 
stenotic site, and the balloon is then inflated2. If stenosis fairly advanced, balloon dilation is 
not enough because the blood vessel walls would recoil and become smaller shortly after 
being enlarged. Hence, the walls have to be supported by stents. A stent is a small, 
expandable wire mesh in a tube form that is used to maintain an artery open after balloon 
angioplasty3 possessing following properties: 
• biocompatibility (non-toxic, non-carcinogenic and non-inflammatory) 
• flexibility 
• visibility under x-ray apparatus (optimal positioning is only possible at sufficiently 
radio-visibility) 
Stent implantation, however, tends to cause injury to the blood vessel resulting in neointimal 
proliferation [development of a thick smooth muscle tissue inside the lumen, ed.], known as 
in-stent restenosis3. Following risks and complications can appear inter alia: 
• stent thrombosis 
• cardiovascular trauma 
• internal bleeding 
• hypersensitivity to contrast medium and narcotics 
• infections 
• embolism (stroke, pulmonary embolism) 
To reduce the risk of thrombosis the patient has to take coagulation inhibitors for at least three 
months. 
  4
1.1.2 Biomaterials, Biocompatibility and Biocompatible Coatings 
A biomaterial is any pharmacologically inert material, viable or non viable, natural product 
or man made, that is a part of or is capable of interacting in a beneficial way with a living 
organism4 (Black) or defined by Williams as any nonliving materials used in medical devices 
intended to interact with biological systems5. Cardiovascular biomaterials can be basically 
divided into three broad categories (Society for Biomaterials Special Interest Groups, SIG): 
• adsorbable polymers (e.g. in case of surgical sutures, short-term applications) 
• non-adsorbable polymers (are permanently implanted inside the patient's body for 
long-term applications, e.g. the biocompatible and under in vivo conditions stable 
polymer polyester is used.) 
• metals (particular noble metals (like gold, platinum) and titanium) 
Next to short-term and long-term applications, tissue engineering is an important application 
field for biomaterials. 
Biomaterials are in direct contact with biological tissue by chemical, physical and biological 
interactions and thus the biological compatibility is an important factor for applications. The 
biocompatibility is defined as The ability of a material to perform with an appropriate host 
response in a specific application6 or revisited by Williams himself for long-term applications: 
The biocompatibility of a long-term implantable medical device refers to the ability of the 
device to perform its intended function, with the desired degree of incorporation in the host, 
without eliciting any undesirable local or systemic effects in that host7. For acceptance or 
rejection of the foreign material, the chemical, physical and structural properties of the 
biomaterial and the tissue response to it are critical factors. 
The interaction between the material and tissue involves: 
• the primary reaction on the material surface occurring within seconds to minutes. In 
most of the cases, the first contact takes place with blood resulting in adsorption of 
blood proteins by hydrophobic interactions between the nonpolar side chain of an 
amino acid and the hydrophobic material surface. Thus, the Protein adsorption plays a 
central role in the short-term and long-term blood biocompatibility of foreign surface8. 
• local tissue reaction caused by immune response. Inert materials show minimal or 
unverifiable reaction with the biological environment and the wound healing processes 
naturally beginning with inflammation and following repairing. At non-inert materials 
the local tissue reaction is significantly stronger and occurs, according to severity, in: 
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o connective tissue encapsulation 
o chronic inflammation 
o creation of granuloma (a compact (organized) collection of mature 
mononuclear phagocytes9 as inflammatory reaction of the immune system) 
o necrosis 
o implant rejection 
• corrosion or degradation of the implant material. Minimal release of corrosion 
products as result of electrophoretic corrosion of the metal has already severe 
consequences, but also polymers may underlie degradation e.g. by hydrolysis, 
oxidation or enzymatic catabolism. 
• systemic effect (long-term effect) as consecutive reaction of the effects occurring on 
the material surface. 
An overview about the types of implant-tissue responses are given in (tab. 1). 
 
If the material is toxic, the surrounding tissue dies. 
 
If the material is nontoxic and biologically inactive (nearly inert), a fibrous tissue of variable thickness forms. 
 
If the material is nontoxic and biologically active (bioactive), an interfacial bond forms. 
 
If the material is nontoxic and dissolves, the surrounding tissue replaces it. 
 
tab. 1 types of implant-tissue response10 
Before surgical placement, all medical implants have to be sterilised to reduce the risk of 
infections and associated complications. The most commonly used sterilization techniques 
utilize heat, steam, radiation or a combination of these methods11. 
Two categories of stent coatings can be distinguished: 
• biocompatible coating to be less thrombogenic and inflammatory, including inert 
materials like carbon, gold and silicon carbide or the neutrally charged phospholipid 
phosphorylcholine, which was found on animal plasma membranes. 
• drug eluting coating (1.1.3) 
Substances that have been examined as stent coatings are listed in (tab. 2). 
Tests of biocompatibility take place in vivo in animal experiments with porcine coronary 
artery as the most commonly used animal model or in vitro with the help of cell or organ 
culture. In the latter case, material properties in comparison to positive and negative controls 
of related materials are examined with regard to cell morphology, growth behaviour and 
metabolic activity. 
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1.1.3 Drug-Eluting Stents (DES) 
Drug-eluting stents (DES) were developed to release drugs, which block the cell proliferation 
and hence prevent restenosis. The drugs, encapsulated in a polymer matrix, are delivered 
directly to the target site minimising the systemic effect. An ideal drug delivery system should 
deliver a drug to a specific site in a specific time and release pattern12. The drug release is 
determined by3 physical mechanisms: 
• diffusion-controlled drug-release (drug diffusion through a polymer layer) 
• dissolution/degradation-controlled drug-release (the drug release is controlled by 
dissolution or degradation of the polymer matrix) 
• ion exchange-based drug-release (ionised drugs bind to the matrix through 
electrostatic interactions and are replaced by ions of the same charge) 
• other controlled release technologies 
and chemical mechanisms: 
• The covalent bonds of drug molecules on a delivery vehicle (so called prodrugs) are 
broken by chemical or enzymatic degradation with a high efficiency in controlling the 
drug-release kinetics. 
Numerous anti-proliferative and anti-inflammatory drugs were assessed; some of them are 
listed in (tab. 2). As of 2004, with DES, the pivotal clinical parameter TVF (target vessel 
failure) is in the upper single-digit range for "standard" lesions and 16% for long lesions13. 
Coating Mechanism of Action 
Biocompatible coatings  
Carbon  Chemically inert and potentially noninflammatory 
Gold  Chemically inert and potentially noninflammatory 
Silicon carbide  Inert semiconductor potentially less thrombogenic and inflammatory 
Phosphorylcholine  Organic polymer potentially less thrombogenic and inflammatory 
Drug coatings  
Anticoagulants  
Heparin  Antithrombotic and possible direct inhibition of smooth muscle cell proliferation 
Hirudin  Antithrombotic and potentially antiproliferative 
Iloprost  Prostacyclin analogue that is antithrombotic and potentially antiproliferative 
Corticosteroids  
Dexamethasone  Corticosteroid with potent anti-inflammatory properties 
Methylprednisolone  Corticosteroid with potent anti-inflammatory properties 
Antimitotic agents  
Paclitaxel  Interferes with microtubule function and thereby inhibits a variety of intracellular 
processes including mitosis and cell migration 
Sirolimus  Inhibits production of proteins essential for cell division; has potent immunosuppressive 
and antimitotic properties 
Angiopeptin  Somatostatin analogue that inhibits many cytokines and growth factors, and potentially 
has antiproliferative effects 
Tyrosine kinase inhibitors  Interfere with intracellular cell signalling that regulate cell proliferation and differentiation 
tab. 2 Substances that have been examined as stent coatings12 
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1.2 Nanoparticles, Drug-Targeting and Controlled Release 
Drugs display a typical distribution in corpora caused by their physico-chemical properties. 
Hence, only a part of the applied drugs reaches the required target location whereas residual 
substances are responsible for side and toxicological effects. Thus, following requirements 
arise for pharmaceutical products: 
• "drug-targeting" (drug carrier under well-directed conditions target to the site of 
(pharmacological) action) 
• "controlled release" (of drugs after reaching the target location) 
• large bioavailability  
• storage stability (protection against environmental influence e.g. air, light and 
humidity) 
• protection against instability in physiological media e.g. enzymatic degradation or 
acidic instability 
Advantage of drug-targeting is the dose reduction with simultaneous improvement of 
therapeutic effectiveness and decrease of unwanted side effects. 
In 1913, Paul Ehrlich (1854-1915) coined the term "Zauberkugel" (magic bullet): 
Wenn wir z.B. eine bestimmte Art eines Empfängers oder Chemorezeptors auffinden würden, 
der nur im Parasiten vorkommt, den Organen des Körpers aber vollkommen fehlt, so würden 
wir einen Stoff haben, der an und für sich vollkommen unschädlich ist und dabei die 
Parasiten radikal vernichtet. Er würde in diesem Sinne genau den Immunprodukten des 
Organismus entsprechen, die ihrerseits nach Art von Zauberkugeln ihren Feind, den 
Parasiten, isoliert treffen14. 
With the aid of nanotechnology, the ability to control or manipulate structures at the atomic 
level was offered to develop effective drug-delivery systems 15 . Nanoparticles are small 
polymeric colloidal particles varying in size from 10-100 nm with a therapeutic agent 
adsorbed, attached, dissolved, dispersed or encapsulated in its polymer matrix 16 . Other 
definitions refer a size range of 1-1000 nm in diameter, comparable to that of an antibody or 
virus20. Thereby nanoparticles (NPs) provide a means for drug transport, envisaged as 'Trojan 
horses'. However, NPs show different properties in biological systems depending on their 
surface (see fig. 1). Thus, their biodistribution is largely determined by their physical and 
biochemical properties, such as particle size, nature of the polymer and drug, and surface 
biochemical properties 17. The polymeric matrixes of "conventional structure" tend to be 
hydrophobic and are readily coated by serum proteins, which act as opsonins. (...) However, 
coating these particles with flexible hydrophilic polymers, particularly polymers containing 
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polyethylene glycol (PEG), can reduce opsonisation of the particles and allow them to remain 
in the circulation for much longer periods18. PEG is in the literature one of the most described 
polymer for "nonfouling" surfaces, which resists the adsorption of proteins and/or cells. By 
means of the hydrophobic/hydrophilic ratio, the biodegradation of NPs can be controlled and 
thus their drug-release over a specific period can be regulated. The release rates depend on: 
• desorption of the surface-bound/adsorbed drug 
• diffusion through the NP-matrix 
• diffusion (in case of nanocapsules) through the polymer wall 
• NP matrix erosion 
• a combined erosion/diffusion process 
Modifying the polymeric NP-matrix with cell-specific ligands such as antibodies, the 
structure becomes "target-oriented". This therapy form is commonly used in chemotherapy, 
too. 
 
fig. 1 Variants of nanoparticle drug carriers19 
Physiological, physicochemical and molecular aspects have to be taken into consideration to 
determine the toxicity of nano-carrier systems. Nanoparticle exposures through the skin, the 
respiratory tract, the gastrointestinal tract and the lymphatics have been described20. Next to 
the polymer matrix, the degradation products of biodegradable NPs and their metabolism are 
critical factors for the biocompatibility. Often described biodegradable NPs as effective drug- 
delivery devices consist of the polymers poly(D,L-lactide), poly(lactic acid) PLA, poly(D,L-
glycolide) PLG, poly(lactide-co-glycolide), PLGA (1.2.1), and poly(cyanoacrylate) PCA21. 
 
 
"long-circulating" and  
"target-oriented" structure 
polymeric  
nanoparticle-matrix 
"conventional" structure 
cell-specific ligands, 
 e.g. antibodies 
"target-oriented" structure 
hydrophilic  
polymer-chains, 
e.g. PEG 
"long-circulating" structure 
"drugs" 
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1.2.1 Biodegradable PLGA-Nanoparticles 
PLGA (poly(lactic-co-glycolic acid)) is a random copolymer of glycolic and lactic acid, 
soluble in dichlormethane, chloroform, acetone, tetrahydrofuran, ethyl acetate, dioxane, 
DMSO and toluene but insoluble in water, ethanol and petroleum ether. The lower the 
percentage of glycolic acid is, the more hydrophilic the polymer becomes. Hence, the ratio of 
glycolic acid to lactic acid determines the rate of degradation, which is generally considered 
as a hydrolytic mechanism. Both in vivo and in vitro studies have identified a heterogeneous 
degradation in large-sized devices (...) characterized by a rate of degradation in the core 
which is greater than that at the surface of the device. (...) microspheres less than 300 
microns in diameter undergo a homogeneous degradation with the rate of degradation of the 
core being equivalent to that at the surface23. Next to the degradation mechanism and rate, the 
size influences the foreign body responses. It is long been known that there is a relationship 
between particle size and spleen uptake, whereas with the increase of size the removal 
increases22. Microspheres greater than 5 to 10 microns in diameter may not be phagocytosed 
within macrophages and foreign body giant cell and thus a foreign body reaction is present at 
the surfaces of these microspheres. Microspheres smaller than 5 microns may undergo 
phagocytosis by macrophages, foreign body giant cells and other types of cells. Incorporation 
of these (...) lead to a more rapid degradation of the biodegradable polyester23. 
PLGA degrades in vivo by hydrolysis into lactic acid and glycolic acid, which are then 
incorporated into the tricarboxylic acid cycle and excreted11. A large number of in vivo and 
in vitro studies have shown the full biocompatibility and biodegradability of PLGA-NPs and 
their degradation products 11, 23, 24. 
PLGA-NPs are produced in laboratory scale by the water-in-oil-in-water (w/o/w) double 
emulsion method (3.10). In clinical applications, PLGA-NPs can be administered orally, 
parenterally or vascularly for site-specific delivery. However, nonspecific adsorption of 
plasma proteins on PLGA micro- and nanospheres is a main limitation of drug targeting25. 
Thereby, the study of Müller et al (2002) has shown a strong decrease of protein adsorption 
on poly(L-lysine)-g-poly(ethylene glycol) (PLL-g-PEG)-coated PLGA microspheres for the 
tested proteins HSA, Fibrinogen, Fibrinonectin and IgG as representative for the human blood 
proteins. 
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1.3 Immune System and Immunisation 
Antibodies against PLGA-nanoparticles were produced by immunisation of rabbits. Thus, a 
short introduction in the immune system is given in (1.3.1). As well for the understanding of 
biocompatibility of biomaterials (1.1.2), it is important to know how the immune system 
reacts. 
1.3.1 Immune System 
In the course of evolution, the immune system of vertebrates evolved "to detect and protect 
against danger". Thereby each immune response involves the recognition of and reaction 
against pathogens or other foreign matters, able to distinguish between foreign and body's 
own. The immune system can be divided into (fig. 2): 
• innate immunity: unspecific acting cells form the first early phase of defence 
mechanism against pathogens. 
• adaptive immunity: developed after some days and acts high specific, differing 
between self and non-self and forming a memory 
The adaptive immunity reacts highly selective to a specific pathogen. 'Remembering' the 
pathogenic agent, the immune response is on the up and up at each infection. Mainly 
responsible for the immune response are: 
• lymphocytes (recognise specific individual pathogens) 
o B-lymphocytes or B-cells 
? formed and matured in the bone marrow 
? able to produce antibodies (Ab) 
o T-lymphocytes or T-cells 
? formed in the bone marrow and matured in the thymus gland 
? control the development and Ab-production of B-cells 
? assist phagocytes to destroy the engulfed pathogens 
? recognise cells infected by viruses and destroy them 
? natural killer cells (NKC) 
• phagocytes 
o monocytes, macrophages, granulocytes 
The immune system is decentrally organised in primary lymphatic organs (bone marrow and 
thymus gland) – involved in production and maturation of lymphocytes – and in secondary 
lymph organs such as spleen and tonsils. The weight of the lymphatic system sums about 2% 
  11
of the body weight. About 1012 lymphocytes circulate in the body, whereby 109 lymphocytes 
are newly-formed per diem. 
 
fig. 2 Diagram of the defence mechanism, both the innate and adaptive immunity26 
As component of the unspecific immune defence, the epidermis with a low acidic pH 
constitutes the first barrier.  
The stages of the specific immune response are illustrated in (fig. 3). 
 
fig. 3 Stages of the specific immune response 
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Invaded pathogens are transported via lymph or blood to the specific cells in the lymph nodes 
and spleen. Antigen-presenting cells (APC) such as macrophages roam the body looking 
towards antigens, commonly a foreign protein molecule of bacteria or other pathogens. APC 
engulfs the antigen and decomposes it in antigenic peptides. The smaller fragments of the 
protein are presented in combination with major histocompatibility complex (MHC-II) on the 
surface of APC. CD4+ T-cells bind specific to this peptide-MHC complex via its T-cell 
receptors (TCR). TCR is non-covalent associated with CD3 (CD = cluster of differentiation) 
and two ζ-polypeptides, which convey the signalling cascade. The T-cell receptor is not only 
specific to the antigenic peptide but also to the presenting MHC, this property is called self-
restriction. By an additional co-stimulating signal of the T-cell receptor CD28 by APC-
receptors of the B7-family (in brief B7:CD28), the T-lymphocytes are activated and the clonal 
expansion is initiated via the growth factor IL-2. The activated T-cells release lymphokines. 
This group of messenger activates B-lymphocytes among other elements of the immune 
system. 
B-cells possess also specific receptors against antigens. However, these receptors recognise – 
in contrast to TCR – non-attached antigens or more precisely a specific configuration of the 
protein. Ag-presenting B-cells, activated through lymphokines, differentiate in antibody-
producing plasma cells. Antibodies (Ab) are free released soluble B-cell-receptors with 
primarily three properties: 
• membrane-bound Ab activate the complement system or other unspecific defence 
mechanisms  
• opsonisation of antigens by free released Ab 
• neutralisation of antigens 
A couple of B- and T-lymphocytes become memory cells and circulate through the body. 
Thus, the immune system is able to response faster when reinfected. 
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1.3.2 Antibodies 
Antibodies (also known as immunoglobulins, Ig) are free released soluble B-cell receptors as 
result of humoral immune response (1.3.1). As a group of glycoproteins, they are found in 
serum and body fluid of all mammalians. In human beings there are five isotypes of 
immunoglobulins (IgG, IgA, IgM, IgD and IgE) differing in size, electric charge, composition 
of amino acids, percentage of carbohydrate and in their function. An overview gives (tab. 3). 
Ig isotypes IgG IgM IgA IgD IgE 
heavy chain γ μ α δ ε 
structure monomer pentamer monomer (> 80%),  dimer monomer monomer 
average serum  
concentration (mg/mL) 14.5 1.5 3.5 0.03 0.00005 
percentage of Ig 70-75% 10 15-20 <1 in traces 
function 
most important Ig 
of the 2nd immune 
response 
predominant 
"early" Ig in 1st 
immune response
mainly in mucosae, 
e.g. saliva unknown parasites, allergy 
molecular weight 146000 970000 160000 184000 188000 
half-life (d) 7-21 10 6 3 2 
distribution 
(% intravascular) 45 80 42 75 50 
percentage of  
carbohydrates 2-3 12 7-11 9-14 12 
sub-groups IgG1, IgG2,  IgG3, IgG4  
IgA1, IgA2,  
sIgA   
tab. 3 Physical-chemical properties of human immunoglobulins27 
The basic structure consists of four polypeptide chains – two small light chains (L) and two 
long heavy chains (H) – connected by disulfide bridges to a Y shape (fig. 4). The type of 
heavy chain (γ, μ, α, δ, ε) determines the isotypes and their subgroups. With mercaptoethanol 
and 6 M urea, the antibody splits into the four parts. Papain cleaves proteolytic in the "hinge" 
region whereby three parts are generated: two identical antigen-binding fragments Fab and one 
crystallisable fragment Fc. Pepsin cleaves elsewhere in one (Fab´)2 fragment and in several 
sub-fragments of Fc. 
Each chain consists of a constant domain (c) and a variable domain (v). Additional to one 
variable domain per chain (vL and vH), the light chain composes of one constant domain (cL) 
and the heavy chain of three (IgG, IgA) or four (IgM, IgE) constant domains (cH1, cH2, cH3, 
cH4). 
 
fig. 4 Structure of immunoglobulin28 
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The theoretical Ab-repertoire of human beings is guessed to about 1011 different specifities26. 
The high diversity is generated by somatic recombination of the variable gene segments (V), 
the diversity gene segments (D) and the joining gene segments (J), also known as V(D)J-
recombination. The gene sequences are encoded on chromosome 14 for the heavy chain and 
on the chromosomes 2 and 22 for the light chains. The light chain is composed of V and J 
sequences and the heavy chain of V, D and J. In the course of the B-cell development in the 
bone marrow, the different gene sequences are stochastic recombined and form the coding 
domain of the variable regions on the light and heavy chain. In addition, the diversity 
increases by somatic mutations. The possibility of the immune system to form antibodies 
against any antigen is utilised in immunisation (1.3.3). 
The variable regions vL and vH consists of 3 hypervariable regions with 5-15 amino acids, 
which form the antigen-binding site, the paratope. The reaction between the paratope and the 
antigen determinant, the epitope, is reversible and given by the affinity constant. The avidity 
is a measure of the binding strength as sum of the primary binding (electrostatic forces) and 
secondary binding (hydrogen bonds, Van der Waals forces and hydrophobic forces). An 
antibody binds specifically to an antigen in a complex mixture but shows also cross-
reactivities to antigens with identical or similar determinants. 
The high affinity and specificity is utilised in immunoanalytical methods (2.2) and in 
immunoaffinity chromatography (2.2.4). 
1.3.3 Immunisation 
Producing polyclonal antibodies, the natural immune reaction of the body against 
immunogenic foreign molecules with a sufficient size (antigens) is taken advance. The 
immune system is described above (1.3.1). Thereby the activation of antigen-presenting cells 
and in the end the differentiation in antibody-producing B-plasma cells and in B-memory 
cells is crucial. Plasma cells survive only a couple of days or several weeks. Hence, they have 
to be replaced continuously by reactivating of memory cells. 
Rabbits, mice, rats, guinea pigs and chickens are commonly used as laboratory animals. Next 
to the ethical husbandry, the susceptibility to stress, the feasibility of applications and the 
desired amount of serum are essential for the choice of animal. Thereby the optimal yield of 
antibodies is achieved with young adults (rabbits 3 months, mice and rats 6 weeks) because 
very young animals are not yet fully immune competent. 
For the formation of antibodies, the concentration of the antigen has to be in a certain range 
(about 10 µg – 1 mg). Out of range, the antibody production fails (suppression of immune 
response, tolerance)29. Antigens with a high immunogenicity generate a high antibody titre 
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and antibodies with a high affinity. However, adjuvants are for the most part necessary when 
immunising with native or soluble antigens or with only a low amount of antigens. Adjuvants 
are auxiliary substances for enhancement and/or extension of the immune response. Thereby 
the sterility and purity of the inoculum is important for the success of immunisation and for 
the stress reduction of animals. Injection methods are efficient when the antigen get rapid and 
well distributed in the lymph nodes and spleen. Subcutaneous is the preferred method for all 
animal species. 
For the stimulation of the memory cells, a lower amount of antigen is necessary in 
comparison to the first immunisation. Booster injections are done without or, if need be, with 
low-stressing adjuvants. Basic procedural steps in immunisation with laboratory animals 
(rabbits) are shown in (fig. 5). 
 
fig. 5 Basic procedural steps in immunisation with laboratory animals (rabbits) 
1.3.3.1 Antibodies against PLGA-NPs 
In summary, although PLA-PGA biomaterials are generally biocompatible and non-toxic, 
several studies have reported inflammatory reactions with the polylactide or polyglycolide 
implants, usually occuring 7-20 weeks after placement in the body11. The aim of this project 
was to produce antibodies against (biocompatible) PLGA-nanoparticles (1.2.1). 
Rabbits were immunised with PLGA-nanoparticles by the company SCIOTEC in cooperation 
with Professor Marcela Hermann and the sera received of them. From the obtained sera, the 
titre was determined and the antibodies against PLGA (PLGA-Ab) were isolated.  
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2nd immunisation 
Booster
blood-test 
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Booster blood withdrawal 
2nd cycle negative 
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1.3.3.2 Determination of Titre 
The titre is a measure of concentration e.g. from antibodies or viruses. For determination, the 
serum is several times diluted and the serial dilutions are tested for the determinative agent 
with immunoanalytical methods such as ELISA (2.2). The titre is the lowest concentration, 
which yields yet a positive reading. 
1.4 Drug-Targeting and Reloading with PLGA-Ab and PLGA-NP 
Nanoparticles are solid colloidal drug-carriers. Depending on its surface, NPs possess 
different properties in biological systems. Equipped with a cognition domain such as 
antibodies (so called "target-oriented" structure), the drug carriers can "dock" to the targeting-
moiety and release site-specific their drugs (1.2). 
PLGA-NPs are biocompatible and one of the most described drug-carriers (1.2.1). By 
immunisation of rabbits, antibodies against PLGA-NP (PLGA-Antibodies) were formed 
(1.3.3). Thus, the surface of PLGA-NP itself acts now as recognition domain for the PLGA-
Ab and no further surface modification of the NP is necessary for targeting. 
However, PLGA-NPs are also biodegradable. Targeted specific to the implant surface via 
recognition by PLGA-Ab, they degrade in lactic and glycolic acid releasing the encapsulated 
drugs. Thereby the conformation changes by and by. The binding to the antibody weakens 
and the nanoparticles dissociate again. Now, the PLGA-Ab is free to bind another drug-carrier 
– drug-reloading can take place. The principle of drug-targeting and drug-reloading with 
PLGA-NPs is schematic shown in (fig. 6). 
 
fig. 6 Principle of the setup for binding PLGA-NPs to implant surfaces via recognition by antibodies 
Next to drug-targeting and decreasing of side effect, new drugs can administered. Thus, 
reloading has - compared with drug-eluting stents (1.1.3) – the main advantage that the 
medication can be adjusted to the specific needs of patients. 
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  17
2 Methods 
2.1 Spectroscopic Methods 
2.1.1 Theoretical Foundations 
The interaction of electromagnetic waves of a certain wavelength and intensity with matter is 
the basis of all spectroscopic methods. As a quantum phenomenon, it is described by wave-
particle dualism. The wave model interprets the electromagnetic waves as a sinus curve with 
the parameter wavelength, frequency, velocity and amplitude; but by this the phenomenon of 
absorption and emission is not proper interpretable. The particle model describes the 
electromagnetic wave as flow of discrete particles, the photons, with the energy E and the unit 
Joule (J) or for the sake of clarity electron Volt (1 eV = 1.6·10-19 J): 
ν⋅= hE  
h = Planck's constant (6.62·10-34 J s) 
ν = oscillation frequency 
The spectrum ranges from long-wave radio- and microwaves (exciting spins) to infrared 
(inducing molecule vibrations) to the short-wave visible and ultraviolet light and X-rays 
(resulting in excitation of electrons). The number of wave trains per cm gives the wave 
number: 
)103(
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sfrequencycmnumberwave  
An overview of the spectrum and applications in spectroscopic methods gives (tab. 4). 
spectrum wavelength wave number [cm-1] 
photon energy 
[eV] excitation of applications 
radio waves 10cm-100m 10-1~10-4 10-5-10-8 nuclear spin NMR 
microwaves 1000-10µm 10-0.1 10-3-10-5 electron spin ESR 
far-infrared (FIR) 30-1000µm 330-10 0.04-0.001 molecular rotation  
mid-infrared (MIR) 3-30µm 3300-330 0.4-0.04 molecular vibration IR/Raman 
near-infrared (NIR) 760-3000nm 13000-3300 1.6-0.4 overtone  
visible (VIS) 400-760nm 25000-13000 3.1-1.6 electrons absorption 
ultraviolet-A (UV-A) 320-400nm 30000-25000 3.9-3.1 electrons absorption 
ultraviolet-B (UV-B) 280-320nm 35000-30000 4.4-3.9 electrons absorption 
ultraviolet-C (UV-C) 100-280nm 100000-35000 12.4-4.4 electrons absorption 
X-ray 0.01-100nm 109-105 105-10 core atomic electrons structure  identification 
tab. 4 Spectrum of electromagnetic radiation and their application in spectroscopic methods30 
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By irradiation of the sample with ultraviolet or visible light, the absorption of a photon effects 
an energy transfer onto the absorbent medium, resulting in an electronic transition. Thereby, 
an electron is raised from ground state S0 (single state) to higher excited discrete states (S1, 
S2 ...) with corresponding vibration levels v while maintaining the spin configuration. Under 
specific conditions, a spin conversion can occur from singlet to triplet state T. 
Return of the excited molecules to the ground state can happen radiationless in consequence 
of internal conversion (IC) or intersystem crossing (ISC) or by emission e.g. fluorescence or 
phosphorescence. The transitions between the energy levels are illustrated in the simplified 
Jablonski diagram (fig. 7). 
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T2
absorption
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fig. 7 Jablonski diagram (IC = internal conversion, ISC = intersystem crossing, S = singlet state,  
T = triplet state, v = vibration level) 
2.1.2 UV/VIS-Spectroscopy 
UV/VIS-Spectroscopy is an absorption method based on the attenuation of a light beam 
caused by electron excitation of atoms and molecules. Atoms absorb photons exclusive by 
excitation of electrons in frontier orbitals. In molecules and complexes, the visible light 
excites non-bonding electrons, π-bonding electron pairs or d-electrons of the central atom. 
Lambert-Beer's law describes the absorbance A of ultraviolet and visible light (UV/VIS): 
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I0 = intensity of the incident light 
I = intensity of the light after passing the material 
ε = molar absorption coefficient (L·mol-1·cm-1) 
c = concentration of the absorbent material (mol·L-1) 
d = distance the light has to travel through (cm) 
The intensity of the light I passed the material decreases exponentially with the concentration 
c of the absorbent material. For characterisation of the absorbance's intensity transmission T 
0I
IT =  
is often used. 
The absorbance measurement in the sample and reference cuvette is simultaneous in a two-
beam photometer. As a light source in the UV-range, a deuterium lamp is usually used and in 
the visible-range a tungsten lamp. The wavelength is determined by a monochromator and the 
beam is divided into two parts by a beam splitter, for reference and sample. Plastic cuvettes 
for visible range absorb ultraviolet light, so use silica cuvettes for absorption below 350nm. 
The signal is detected by photomultiplier. 
2.1.3 Fluorescence-Spectroscopy 
The excitation of S0, v = 0 results in excited states S1 and S2 with vibration levels v = 0 or 
higher. By internal conversion (IC) thermal equilibration occurs to S1, v = 0 before relaxing to 
the ground state is possible (fig. 7). Hence the fluorescence spectrum is shifted to lower 
energies and thus to higher wavelengths in contrast to the absorbance spectrum, called Stoke-
shift. The fluorescence lifetime refers to the average time the molecules stay in the excited 
state before emitting a photon and ranges in the order of magnitude 10-9 – 10-7 s. The 
fluorescence intensity F is depending on the concentration c of the molecule to be analysed: 
)303.2(0 dcIF ⋅⋅⋅⋅⋅= εφ  
I0 = intensity of the intrinsic light 
 = quantum efficiency 
ε = molar absorption coefficient (L·mol-1·cm-1) 
d = thickness of the cuvette (cm) 
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The most intensive fluorescence is observed at molecules with functional aromatic groups 
low-energetic π → π* transition states. Fluorescence extinction occurs by collision of excited 
molecules with other particles like low-molecular compounds, ions or solvent itself and the 
transfer of energy; thus, the probability of emission decreases - the phenomenon of quenching. 
Too high concentrations of fluorescent molecules also result in extinction by self-relaxation. 
As light source, mercury or xenon high-pressure lamps are used. The wavelengths for 
excitation (λexc) and emission (λem) are selected by monochromators before and after the 
sample. The photomultiplier is aligned perpendicular to the intrinsic light beam. 
2.2 Immunoanalytical Methods 
2.2.1 Theoretical Foundations 
Immunoanalytical methods are based on the specific interactions between immunoglobulins 
(Ig) and antigens (Ag); hence, in most of the cases no sample preparation is necessary. 
Utilising the high affinity, immunoaffinity chromatography (2.2.4) is one of the most efficient 
separation methods in biochemistry. Immunoassays (IA) are rapid tests, divided in: 
• Immunoprecipitation 
• competitive IA 
• non-competitive IA 
Immunoprecipitation requires at least two or three antigen determinants. Loss of solubility 
caused by stoichiometric binding of antibodies (Ab) to the paratopes results in agglutination 
used e.g. in Ouchterlony double immuno diffusion. 
The competitive assay is mainly applied for antigens with only one paratope. The 
immobilised antibody is incubated with a solution of antigen and labelled antigen, then both 
compete for binding. The detection occurs by measuring the signal of the increase of labelled 
antigen bound or by its decrease in solution. 
Working with non-competitive IA either Ab or Ag can be immobilised. When adding the 
analyte, a direct correlation between the concentration and the signal is observed. Working 
with labelled analytes allows for direct detection of the signal. However, the indirect method 
requires a second labelled antibody to target the bound analyte. At the "sandwich assay", the 
Ag is encased between the immobilised and labelled secondary antibody. 
The homogeneous assay creates the signal by formation of Ab-Ag complex, so no further 
separation is necessary. In contrast, with a heterogeneous assay, the labelled analyte bound 
and free in solution would give the same signal and therefore separation is essential before 
detection is possible. The separation can be carried out e.g. by immobilisation onto a solid 
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phase and removing the supernatant by washing. 96-well-Microtiter plates are commercially 
used binding proteins unspecific onto a polystyrol layer. The automation makes screening of a 
large sample number possible. Another possibility is the immobilisation onto polystyrol-
coated beads with iron core; the bound analytes are removed simply by magnet. 
By means of labelling and type of detection, it is possible to distinguish: 
• radio immunoassay (RIA) 
• enzyme-linked immunosorbent assay (EIA, ELISA) (2.2.2) 
• fluoro immunoassay (FIA) 
• cluster-linked immunosorbent assay (CLISA) (2.2.3) 
Important for development of immunoassays is the type of antibody, monoclonal or 
polyclonal, and its affinity and cross reactivity (specificity). 
2.2.2 ELISA 
The principles of enzyme-linked immunosorbent assay (ELISA) are described above (2.2). 
The labelling of analyte with enzyme has many advantages over RIA and FIA e.g. by 
avoiding radioactivity or photobleaching. The most commonly used enzymes are alkaline 
phosphatase (ALP, 2.2.2.1) and horseradish peroxidase (HRP, 2.2.2.2), which convert a 
colourless substrate into a dyed product. Immunohistochemical staining occurs by an 
insoluble product. 
Important for the choice of enzyme to be labelled is the conjugation on molecules, its 
specificity and turn over rate and the detection limit of the product, but also its robustness and 
independence from reaction parameters like pH and temperature. 
2.2.2.1 Alkaline Phosphatase (ALP) 
Alkaline phosphatase (Orthophosphoric-monoester phosphohydrolase (alkaline optimum); EC 
3.1.3.1)31 is an ubiquitous isoenzyme with the highest activity at pH 8-10, but instable and 
inhibited in acidic solution. The most utilised isoenzyme is isolated from calf intestine with a 
molecular weight of 140 kDa and a turn over rate of 3500 s-1. ALP is a metalloenzyme with 
two Zn2+ and one Mg2+ at each active site 32 , hence metal chelators like EDTA act as 
inhibitors. The enzyme catalyses the phosphoric ester hydrolysis of an orthophosphoric 
monoester while creating alcohol and orthophosphate. 
As a very sensitive detection of ALP, a solution of BCIP (5-bromo-4-chloro-3-
indolylphosphate) and NBT (nitro blue tetrazolium chloride) can be used (fig. 8). 
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fig. 8 Staining with BCIP and NBT 
Both with a very little solubility generate insoluble products applied for the ALP-detection in 
immunoblotting and immunohistochemical assays. BCIP, the substrate for ALP, is 
dephosphorylated under hydrolysis and reacts further by dimerisation to a dark-blue insoluble 
indigo dye, an oxidation product reducing NBT to the blue precipitate diformazan. Thereby 
NBT intensifies the colour and makes detection more sensitive. 
2.2.2.2 Horseradish Peroxidase (HRP) 
Horseradish Peroxidase (Donor: hydrogen-peroxide oxidoreductase; EC 1.11.1.7)33 is one of 
the most popular enzymes used in antibody labelling. With a molecular weight of 40 kDa it is 
comparatively small and stable. HRP is a glycoprotein with at least seven isoenzymes. It 
catalyses the redox reaction of hydrogen peroxide with electron-donating substrates under 
formation of water and oxidised donor, its optimum pH is 7. The oxidation of an electron 
donor is utilised to create a coloured product. 
H2N NH2
TMB, λmax=285nm
-e-
H2N NH2
H2N NH2
HN NH
1/2 H+
λmax=370, 652nm
-e-
HN NH
λmax=450nm
2H+
 
fig. 9 Oxidation of TMB to a blue and a yellow product 
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TMB (3,3’,5,5’-tetramethylbenzidine) is a chromogenic solution and oxidised during the 
enzymatic degradation of hydrogen peroxide forming a blue colour with wavelength of 
652nm, a blue charge-transfer complex of the parent diamine and the diimine oxidation 
product. This species exists in rapid equilibrium with the radical cation34. After stopping the 
reaction with acidic solution, a stable yellow diimine is formed and can be measured at 
450nm (fig. 9). 
2.2.3 Gold Cluster Labelling as an Alternative to ELISA 
The gold cluster colloids (GCC) were prepared according to Frens 35  by reduction of 
chloroauric acid (HAuCl4) with trisodium citrate leading to particles with negatively charged 
surface, so-called ζ-potential. The size of GCC decreases with the increase of the power and 
concentration of the reducing agent. The DLVO theory (named after Derjaguin, Landau, 
Verwey and Overbeek) describes the stability of colloidal suspensions based on attractive 
forces and negatively charged repulsion. Electrolytes like sodium chloride in buffer destroy 
the ζ-potential leading to coagulation. The colloids can be stabilised by adding proteins or 
blocking agents like fish gelatine or Tween20 (4.2.1). 
The adsorption of proteins on GCC occurs spontaneously. Preparation of stable protein-gold 
complexes depends on several interactions36: 
a) the electronic attraction between the negatively charged gold particles and the 
abundant positively charged sites on the protein molecule, 
b) an adsorption phenomena involving hydrophobic pockets on the protein binding to the 
metal surface, and 
c) the potential for covalent binding of gold to free sulfhydryl groups, if present. 
The cluster linked immunosorbent assay (CLISA, fig. 10) was developed by Haifa Al-Dubai 
in the research group of Professor Pittner and constitutes an inexpensive alternative to ELISA. 
 
 
fig. 10 CLISA (cluster linked immunosorbent assay): A dot-blot test using gold colloid cluster technology37 
(see also attachment) 
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Dotting of additional buffer onto the nitrocellulose membrane with a protein dot, results in a 
protein-monolayer. After drying for 1h at rt, the membrane has to be blocked and washed. 
Thereafter, incubation takes place in GCC labelled antibody solution for 2h. Washing again 
the signal is detectable by visual colourimetry. Comparing with the signal of protein dots of 
known concentration, a semi-quantitative valuation is possible. The color reaction product is 
stable for a very long time and does not fade. The sensitivity of the method is comparable to 
that of ELISA if not better and furthermore needs only small amounts of antibody for 
detection or for GCC-labeling37. 
2.2.3.1 Signal Amplification with Protein G 
An additional signal amplification is achieved by means of protein G, a protein of the 
Streptococcal bacteria cell wall. It has three homologous domains, which bind with a high 
affinitiy to the Fc fragment of immunoglobulins, primary IgG. Protein G is commonly used in 
affinity chromatography to purify antibodies, too. 
Adding the protein G to the GCC solution it binds to the negatively charged surface of the 
gold clusters with simultaneous preventing coagulationg by blocking the surface. Now, the 
immunoglobulins can be bound to the protein G, with theoretically three antibodies per 
protein. In practise, the GCC are more stable and the signal is several times amplified. 
2.2.4 Affinity Chromatography 
The affinity chromatography is a highly selective separation method based on reversible 
interaction of the ligand with its target molecule such as between antigen (Ag), protein A or 
protein G with antibody (Ab) and substrate or cofactor with enzyme. Biospecific interactions 
for affinity chromatography typically show affinity constants in the range 10-5 – 10-7 M. At 
higher values the binding is too weak to efficiently retain the target molecule and lower than 
10-8 M the elution is difficult. In immunoaffinity chromatography, an Ag as ligand is used to 
separate antibodies. 
The ligand is covalently coupled to a chemically and physically inert matrix, the stationary 
phase, via a spacer arm to overcome sterical hindrance and thus to improve the binding 
between ligand and target molecule. Packed into a column, equilibration occurs with binding 
buffer, which is optimised for effective interactions. Loading the sample, the target molecule 
is retained by the affinity medium while unbound molecules are washed through the column 
with several of column volume of washing buffer (often the binding buffer is used to wash). 
The elution buffer reverses the interaction and hence elutes the target molecules. The 
weakening of the binding can occur either by changing pH, ionic strength or polarity and thus 
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changing the Ab conformation or by adding a substance that competes for binding. The 
elution should be done fast to achieve an enrichment of the analyte. Afterwards, the eluate has 
immediately reconditioned to avoid denaturation. 
The detection of the analyte can be unspecific e.g. by UV-absorption of aromatic side chains 
of proteins at 280nm, or by Bradford Assay (3.5.1) or can be specific by measurement of the 
biological activity e.g. by enzymatic assays and immunoassays. 
After regeneration of the matrix, the column can be reused several times. 
Important purification parameters are 
proteinmg
proteintheofuniticallogbioactivityspecific =  
)()( proteinsofamounttotalactivityspecificactivitytotal ⋅=  
sampleoriginalofactivitytotal
fractioninactivitytotalyecoverr =  
Ideally the specific activity increases and the recovery = 1. 
2.3 PAGE - Polyacrylamide Gel Electrophoresis 
2.3.1 Theoretical Foundations 
The electrophoretic process is the separation of charged particles in an electric field. The 
balance between the accelerative forces Fe affecting to the charge q 
EqFe ⋅=  
E = electric field strength 
and the friction force Ffr 
vfF cfr ⋅=  
fc = frictional coefficient 
v = particle's velocity of migration 
effects a constant velocity of the particle: 
Eu
f
Eqv
vfEqFF
c
cfre
⋅=⋅=⇒
⋅=⋅= ;
 
u = electrophoretic mobility, substance specific. 
 
 
 
  26
Stoke's law describes the friction force for small spherical objects: 
rfc ⋅⋅= ηπ6  
η = fluid's dynamic viscosity 
r = radius of the spherical object 
Therefore, for the velocity v follows from above: 
r
Eqv ⋅⋅
⋅= ηπ6  
This means that the velocity of the particle is proportional to its total charge and the applied 
field strength and reciprocally proportional to its size and the fluid's viscosity. In an electric 
field, particles differing in charge-to-radius ratio migrate with different velocities in the gel 
and can thus be separated. Using supporting materials with high viscosity and defined pore 
size (e.g. agarose and polyacrylamide gels), the separation by size of the molecules is 
improved. 
For non-spherical molecules like peptides and proteins an empirical relationship between the 
mobility u and the molecular weight MW is given by: 
3/2MW
qu ≈  
The spectrum of electricity suppliers ranges from 200V at 400mA to 500V at 150mA 
depending on the applied method. The current is maintained by electrolysis on both electrodes, 
changing the buffer by and by: 
2e- + 2H2O 2OH- + H2
2H+ + 1/2O2 + 2e
-H2O
cathode
anode
 
During electrophoresis, Joule heating W is developed per unit of volume: 
cEW ⋅⋅= λ2  
λ = equivalent conductivity 
c = molar concentration of the electrolyte 
With increase of the temperature, the resistance decreases. In addition, the fluid evaporates 
faster and the concentration of the electrolytes increases, which results in a slowdown of the 
sample movement and band broadening. Another aspect of the heat is the denaturation of the 
proteins and an altered electrophoretic mobility. 
Besides the pore size and temperature, the buffer system and the salt concentration are 
important factors for an optimal separation influencing not only the current via ion strength 
but also the charge and conformation of the proteins. 
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2.3.2 Polyacrylamide Gel 
Polyacrylamide is formed by radical polymerisation of acrylamide. The chain reaction, started 
by ammoniumpersulfate (APS), is catalysed by tetramethylethylenediamine (TEMED). N,N´-
methylenebisacrylamide (Bis) cross-links the linear polyacrylamide chains (fig. 11). The 
polymerisation occurs under exclusion of air because oxygen leads to chain reaction 
interruption. 
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fig. 11 Polymerisation and crosslinking of acrylamide 
The pore size is determined by the total amount of acrylamide T: 
%100)( ⋅+=
m
baT  
and the amount of crosslinker C: 
%100
)(
⋅+= ba
bC  
a = acrylamide [g] 
b = crosslinker [g] 
m = volume of buffer [cm3] 
A discontinuous electrophoresis is applied to narrow bands of the separated proteins using 
two gel systems differing in pore size and pH. The samples are loaded onto the short and 
large-pore stacking gel with pH 6.8, about two units lower than the running buffer. By the 
process of isotachophoresis, a stacking effect occurs resulting in a pre-separation and 
enrichment. Arriving at the small-pore separating gel with higher ionic strength (pH 8.4) a 
compression and an additional band narrowing is the consequence. In the separating gel, the 
proteins are separated then by electrophoretic principles. 
To monitor the electrophoretic process bromophenol blue is used as a front marker. 
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2.3.3 Native-PAGE 
Native gel electrophoresis is a technique that separates the proteins by their mass-to-charge 
ratio. Avoiding detergents like SDS, the separated proteins are not denatured and keep their 
physical properties. Hence, specific properties of the proteins can be utilised for selective and 
sensitive detection. For example, the enzyme activity or the antibody-antigen interaction can 
be detected directly in the gel or on nitrocellulose membrane after Western Blot by enzymatic 
or immunological methods. 
2.3.4 SDS-PAGE 
SDS (sodium dodecylsulfate) is an anionic detergent, denaturing secondary and non-disulfide-
linked tertiary protein structure. In excess over the proteins, it covers their charges 
accumulating micelles with negative charge with about 1.4 g SDS per g protein. During 
sample preparation, the hydrogen bridges are broken by heating to 95°C for 5min and the 
molecule is stretched. Adding reducing agents like dithiothreitol (DTT), the disulfide bonds 
are reduced, too. The uncurled and with SDS loaded peptide chains can be separated now by 
their molecular weight. 
2.3.5 Detection and Quantification of the Separated Proteins 
After separation, the proteins have to be fixed in the gel with methanol/acetic acid/water 
solution, which denature and precipitate the proteins or the proteins can be blotted onto 
nitrocellulose membrane by Western Blot (2.4).  
The proteins can be visualised by staining with e.g. Coomassie Brilliant Blue (CBB) or 
PonceauS (fig. 12). In acidic solution, CBB binds unspecific to basic amino acids, primary 
arginin, with an absorbance shift from 465nm to 595nm. CBB is also utilised for Bradford-
Assays (3.5.1). PonceauS binds to positively charged amino acids, staining proteins reversibly. 
Hence they can be used for further applications. 
N
N
HN
SO3H
SO3
-O
Coomassie Brilliant Blue
HO3S N
N
SO3H
N
N
HO SO3H
SO3H
Ponceau S
 
fig. 12: Stains: CBB and PonceausS 
Furthermore, enzymatic or immunological methods (2.2) take advantage of specific properties 
of the proteins for sensitive and specific detections. 
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2.4 Western Blot 
After electrophoresis, the separated proteins can be transferred from the polyacrylamide gel to 
nitrocellulose or polyvinylidene difluoride (PVDF) membrane by diffusion, capillary action 
or electroblotting. For the electrophoretic transfer a standard tank or semi-dry blotting system 
is used. 
For semi-dry blotting, the blot sandwich soaked with transfer buffer is placed - free from air 
bubbles - between two graphite plates in following set-up: anode/ 3 sheets of Whatman® filter 
paper/ gel/ nitrocellulose membrane/ 3 sheets of Whatman® filter paper/ cathode. An electric 
field vertical to the gel elutes the proteins out of the polyacrylamide gel and transfers them 
onto the membrane. The experiment runs at constant current of 1mA per cm2 blot area. For a 
quantitative elution, pH and ionic strength of the SDS-free transfer buffer should agree with 
the running buffer of electrophoresis. At beginning, low voltages (<5V) are generated but 
increase by and by with the increase of ohmic resistance up to 20-50V. By electrolysis of 
water, a pH gradient is generated (ranging from pH 12 on the cathode to pH 2 on the anode) 
as well as gas evolution38. To avoid non-uniform voltage caused by pushing apart the blot 
sandwich because of gassing, weight down the blotting equipment. 
The proteins adhere on the nitrocellulose membrane by hydrophobic interactions and can be 
detected directly on the membrane by immunological and enzymatic methods (2.2.4). 
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3 Experimental Section 
3.1 Gold Cluster Labelling Test 
a) Gold Cluster labelling of antigen (or antibody):  
Prepare 1 mL 1% HAuCl4 in ddH2O and dissolve it in a very clean Erlenmeyer flask covered 
with aluminium foil in 100 mL ddH2O under stirring until boiling. Add rapidly 4 mL of 
filtered 1% trisodium citrate solution and heat for another 10 min while the colour changes to 
red. Cool down the solution at rt. 
For labelling the gold cluster colloid (GCC) take 10 mL of the solution and add about 1 to 10 
µL of the respective antigen or antibody. Check the correct concentration by adding an aliquot 
of NaCl to a portion of the GCC solution – if coagulation occurs, add more of the respective 
proteins to stabilise the GCC. To block the residual surface of the cluster add 1 mL of the 
blocking solution (1% fish gelatine in water, avoid electrolytes like sodium chloride). 
For signal amplification, protein G can be added first to the GCC solution before labelling 
with antibodies. 
The labelled and blocked GCC can further be concentrated by centrifugation at 14000 rpm for 
10 min and resolving the precipitate in an aliquot of the supernatant. 
b) Dotting of antibody (or antigen) onto nitrocellulose membrane: 
In the meantime, dot 1 µL of the respective antibody (or antigen) onto the nitrocellulose 
membrane. Dotting of additional 5 µL buffer onto the same spot enlarges the spot obtaining a 
protein monolayer. After drying for 1 h at rt, block for 30 min with the blocking solution and 
wash 3x for 5 min with the washing solution and 3x shortly with ddH2O. In this case, the 
washing steps are important to remove electrolytes such as sodium chloride to prevent 
coagulation of GCC. 
Now incubate with the gold cluster labelled antigen (or antibody) as prepared according to a) 
for 2 h. To remove unspecific bindings of gold cluster with the nitrocellulose membrane wash 
3x 5 min with the washing solution.  
Blocking solution: 
gelatine from cold water fish skin  2 g 
Tween20     100 µL 
50 mM Tris/HCl, 0.15 M NaCl, pH 7.3 100 mL 
Washing solution: 
Tween20     1 mL 
50 mM Tris/HCl, 0.15 M NaCl, pH 7.3 200 mL 
  31
3.2 Biocompatible Coating 
3.2.1 Etching of Aluminium, Steel and Titanium 
To obtain hydroxyl groups for further aminosilanisation (3.2.2), etch the different materials 
like aluminium, steel (Fe/Cr18/Ni8) or titanium with 3% HNO3 solution for 10 min. After 
repeated washing with ddH2O, soak them for two days in water. 
3.2.1.1 Detection of Iron – Verification of Effective Etching  
Prepare a Whatman® filter paper moistened with 5% NaSCN and then dry at rt. Take 1 mL of 
the supernatant of the 3% HNO3 solution over steel (3.2.1) and add 50 µL of 1% H2O2. Dot a 
few µL of this solution onto the Whatman® filter paper. If the reaction is positive, the colour 
will turn to red. 
Fe2+ Fe3+
H2O2
Fe3+ 6 SCN- [Fe(SCN)6]3-
(red)  
fig. 13 Detection of iron 
3.2.2 Coupling of Organosilane to Inorganic Surface 
Hydroxyl groups of an inorganic surface can be reacted with APTS (3-
Aminopropyltriethoxysilane), a popular organosilane to create functional amino groups on 
inorganic surfaces. The reaction can be performed either by aqueous or by organic solvent 
deposition. 
OH NH2(CH2)3(C2H5O)3Si
(3-aminopropyl)triethoxysilane
O Si (CH2)3 NH2
 
fig. 14 Hydroxyl groups of inorganic surface reacted with APTS 
3.2.2.1 Organic Solvent Deposition 
At first, wash the slides, glass powder or the etched materials respectively (3.2.1) with 
isopropanol and ddH2O. In the meantime, prepare a 5% (3-aminopropyl)triethoxysilane 
solution in 95% ethanol. Shake the slides for 1 h in the solution and wash 3x with 95% 
ethanol afterwards. Keep o/n at 110°C. 
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3.2.2.2 Aqueous Deposition 
Wash the slides, glass powder or the etched materials respectively (3.2.1) with isopropanol 
and ddH2O. In the meantime, prepare a 10% (3-aminopropyl)triethoxysilane solution with 
ddH2O and adjust with HCl to pH 3.5. Shake the slides in the solution for 2 h at 75°C and 
thereafter wash 3x with ddH2O. Keep o/n at 110°C. 
3.2.3 Introduction of Carboxylate Groups 
Prepare a 0.4 M succinic anhydride solution in 50 mM PBS, pH 6 and add this to the 
aminopropylsilane coated slides (3.2.2). Shake the slides in the solution o/n and wash then 3x 
5min with 50 mM PBS, pH 6 and 3x with ddH2O. 
O OO O Si (CH2)3
H
N C
O
(CH2)2 C
OH
O
= R
O
OH
O Si (CH2)3 NH2
aminopropyl silane
coated surface
succinic anhydride
 
fig. 15 Reaction of amino groups with succinic anhydride 
3.2.4 EDC – A Zero-Length Crosslinker 
EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) is an often used 
carbodiimide for coupling of carboxylates with amines. Avoid buffers containing free amines 
like Tris or glycine. 
H3C NH
N
O
R
O
H
NH3C N
C
N NH
Cl
1-ethyl-3-(3-dimethylaminopropyl)carbodiimid Cl
R
O
OH
 
fig. 16 Activation of carboxyl groups with EDC 
Dissolve 400 mg EDC in 50 mL ddH2O or buffer and adjust with NaOH to pH 10. Shake the 
slides prepared with succinic anhydride (3.2.3) in this solution for 1.5 h. Wash the slides with 
ddH2O repeatedly. 
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3.2.4.1 EDC plus Sulfo-NHS 
Sulfo-NHS (sulfo-N-hydroxysulfosuccinimide) increases the yield of EDC-mediated 
reactions several times over. 
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fig. 17 Activation of carboxyl groups with EDC and sulfo-NHS 
Dissolve 400 mg EDC and sulfo-NHS (final concentration 5 mM) in 50 mL 0.05 M PBS, pH 
6. Shake the slides prepared with succinic anhydride (3.2.3) in this solution for 1.5 h. Wash 
the slides with ddH2O repeatedly. 
3.2.5 Pegylation 
Dissolve 1 g O,O′-bis(3-aminopropyl)polyethylene glycol (bisamino-PEG) in 50 mL 
carbonate-bicarbonate buffer, pH 10 or in 50 mL citric acid-sodium citrate buffer, pH 5. 
Shake the slides prepared with EDC or EDC plus sulfo-NHS respectively in this solution o/n. 
Wash the slides with ddH2O repeatedly. 
H2N
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O NH2n -EDC
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N C
O
(CH2)2 C NH
O O
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N
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R
O
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N
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fig. 18 Pegylation 
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3.3 Verification of Biocompatible Coating by Surface Labelling 
3.3.1 Staining with TNBS 
TNBS (2,4,6-trinitrobenzenesulfonic acid solution) reacts with molecules forming highly 
chromogenic derivatives orange-coloured with an absorbance of 335nm. TNBS was used to 
stain the amino groups of the biocompatible coating on slides (3.2). As shown in (fig. 19), 
TNBS reacts under relatively mild alkaline conditions to produce an unstable Meisenheimer 
complex. Subsequent acidification to pH 1 rapidly converts the orange unstable product to a 
yellow stable trinitrophenol (TNP) derivative39. 
NH2R
N
S
N N
O
O
O
O
O
O
O
O
O
trinitrobenzene sulfonic acid
NO2
-O3S
O2N NO2
RHNpH 8.4 1 M HCl
NO2
O2N NO2
RHN
Meisenheimer complex
(orange, unstable)
TNP-amino acid
(yellow, stable)  
fig. 19 Detection of amino groups with TNBS 
Prepare freshly a 0.01% (w/v) TNBS-solution by dilution of 20 µL 5% (w/v) stock solution 
(Sigma) with 0.1 M sodium bicarbonate buffer, pH 8.4. Shake the (amino group containing) 
slides for 2h at 37°C in this solution Add 1 mL 10% SDS and 0.5 mL 1 M HCl to each sample. 
3.3.2 Staining with OPA 
OPA (O-phthaldialdehyde) was used to stain the biocompatible coating on slides (3.2). It 
reacts with amino groups in presence of thiol-containing molecules like 2-mercaptoethanol to 
a fluorescence product with an excited wavelength λexc = 360nm and an emission wavelength 
of λem = 455nm. Detection limits for proteins in liquid are in the range of µg/mL. 
NH2R SHR
OH
OH
O
O
O-phtaldialdehyde
N R
S R
 
fig. 20 OPA - fluorescence reaction for amino groups 
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Add to 1 mL 50 mM borate buffer, pH 9.2 250 µL OPA (20 mg/mL) and 250 µL 2-
mercaptoethanol or cleaved antibodies respectively (3.6.3). React the slides in this solution 
for 1h and wash them with ethanol thereafter. The marking of amines from the biocompatible 
coating (3.2) by OPA was observed under the fluorescence microscope Olympus BX41 using 
an excitation wavelength of 360nm and an emission wavelength of 436nm. The photos were 
taken by ColorView (Soft Imaging System) with resolutions 10x (N.A 0,25), 20x (N.A 0,40), 
40x (N.A 0,65) and 60x (N.A 0,80) and edited with the Cell^D life science documentation 
software. 
3.4 PLGA-Antibody Purification 
3.4.1 Immobilisation of PLGA onto Glass Powder 
Dissolve 450 mg PLGA (poly(lactic-co-glycolic acid, 50:50, MW 07462) in 20 mL dioxane 
and 100 mg EDC and 100 mg sulfo-NHS in 10 mL ddH2O. Pool both solutions and stir for 1 
h. Add 5 g aminosilanised glass powder (3.2.2) and react o/n. Wash the glass powder in a 
suction filter, pore size 4, with 3x dioxane, 3x dioxane/ddH2O and 3x ddH2O. 
3.4.2 Purification of PLGA-Ab with PLGA-Affinity Chromatography 
Fill a 3 mL column with PLGA conjugated glass powder (3.4.1) and wash with at least 4 
column volumes of binding buffer (5 mM PBS, 0.15 M NaCl, pH 7.2). Dilute the rabbit 
serum immunised with PLGA 1:5 with binding buffer and apply this on the column with 0.15 
mL/min. Wash the column with binding buffer until no more proteins can be detected by 
Bradford protein assay (3.5.1). Elute with the elution buffer (0.1 M acetic acid/ 0.1 M NaOAc, 
pH 3) and a flow rate of 1.7 mL/min. Collect the fractions in micro wells, put in first the 
neutralisation buffer (0.5 M NaHCO3). For neutralisation about 8 µL neutralisation buffer are 
in need of 2 drops elution buffer. The proteins are detected with Bradford protein assay 
(3.5.1), this fractions pooled and adjusted to pH 7. The concentration was determined with 
Quant-iT™ Protein Assay Kits (for use with the Qubit™ fluorometer, Invitrogen, 3.5.2). 
If necessary, the sample can be concentrated by adding dry Sephadex25 and suck off. 
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3.5 Protein Assays 
3.5.1 Bradford Protein Assay 
Coomassie Brilliant Blue (see also 2.3.5) stains proteins in acidic solution by unspecific 
binding to cationic and non-polar, hydrophobic side chains of proteins resulting in an 
absorbance shift from 465nm to 595nm. The method is named after M. M. Bradford. 
Add your sample to 1 mL Bio-Rad Protein Assay (Bio-Rad Laboratories, 1:5 diluted). After 
10 min incubation, measure the colour change at 595nm against a blank value. The calibration 
curve is prepared with BSA-standards. 
For a qualitative determination of the proteins, to find the fractions after elution from the 
affinity chromatography (3.4.2), 20 µL Bio-Rad Protein Assay 1:5 diluted were added to 10 
µL of each fractions and the colour change to blue observed. These fractions were pooled. 
3.5.2 Quant-iT™ Protein Assay Kit (Invitrogen) 
The Qubit™ Fluorometer is calibrated with three BSA standards (0 ng/µL, 200 ng/µL and 
400 ng/µL in TE buffer with 2mM sodium azide). 10 µL of each standard is diluted in 190 µL 
Quant-iT™ working solution, prepared by diluting the Quant-iT™ protein reagent 1:200 in 
Quant-iT™ protein buffer and measured after 15 min incubation at rt. 
Dilute 1-20 µL of your sample in Quant-iT™ protein buffer to obtain finally 200 µL solution. 
Mix well and measure the protein concentration after 15 min incubation with the Qubit™ 
Fluorometer. The concentration of the sample is calculated using the following equation: 
x
valueQFsampleyourofionConcentrat 200×=  
QF value = the value given by the Qubit™ fluorometer and 
x = the number of microlitres of sample you added to the assay tube. 
3.6 Cleaving Disulfide with Immobilised Dihydrolipoamide 
Immobilised dihydrolipoamide for the reduction of disulfides was used first by Gorecki and 
Patchornick in 1973 40 . Lipoic acid (6,8-dithiooctanoic acid) can be immobilised to 
aminosilanised glass powder via the carboxylic acid group with the help of EDC. Afterwards 
the cyclic disulfide is reduced with NaBH4 (or Na2S2O4 respectively) to the thiol 
dihydrolipoamide, which is able to reduce disulfides and antibodies. This method has the 
advantage of batch processing and the reagent dihydrolipoamide can easily be removed and 
thus no contaminating by-products are produced. Furthermore, after regeneration with NaBH4 
(Na2S2O4) the reaction with immobilised dihydrolipoamide can be repeated several times41. 
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3.6.1 Immobilisation of Lipoic Acid onto Glass Powder with EDC 
Lipoic acid is not soluble in aqueous solution in contrast to EDC. Therefore, I decided to use 
a dioxane/water mixture to bring both of the reagents in one phase.  
Dissolve 1 mmol lipoic acid in 10 mL dioxane and 2 mmol EDC in 10 mL ddH2O. After both 
reagents are dissolved, mix the solutions and stir for 1h at rt. Now add 5g amino-silanised 
glass powder (3.2.2) and stir o/n. By that procedure, some of the lipoic acid will precipitate 
when added to the aqueous solution of EDC but the result is much better than by using only 
an aqueous solution or buffer. Finally wash several times with dioxane and water.  
3.6.2 Reduction of Lipoamide to Dihydrolipoamide 
R NH2 OH
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O
R N
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O
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lipoic acid
dihydrolipoamide
aminopropyl silane
coated surface
lipoamide
EDC
 
fig. 21 Immobilisation of lipoic acid and reduction to dihydrolipoamide 
Wash the glass powder coated with lipoic acid (3.6.1) 3x with dH2O and ethanol. Add 10 mL 
ddH2O, 2.5 mL EtOH and 200 mg NaBH4. Shake for 1 h at rt, add another 200 mg NaBH4 
portion to the solution and shake for further 5h. Reduce the rest of NaBH4 with 6N HCl until 
the development of gas has stopped. Wash the glass powder with ddH2O. Na2S2O4 can also be 
utilised as a reducing agent instead of NaBH4. 
The proof of the immobilisation of lipoic acid on glass powder is given by Ellman's assay 
(3.7): Adding 50 µL Ellman's reagent to 50 mg on glass immobilised lipoic acid and 1 mL 
0.1M PBS, pH 8 results in yellow staining with an absorbance of A=0.255. The negative 
control without lipoic acid shows an absorbance of A=0.101.  
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3.6.3 Cleaving Antibodies with Immobilised Dihydrolipoamide 
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fig. 22 Antibody split by immobilised dihydrolipoamide 
Add 1 µL of the antibody to 1 mL 0.1 M PBS, pH 8 and 0.5 g glass powder with immobilised 
dihydrolipoamide (3.6.2) and shake for 30 min. The supernatant with the split antibodies is 
used for further experiments. 
3.7 Ellman's Assay 
Ellman's reagent (5,5´-dithio-bis-(2-nitrobenzoic acid), DTNB, Pierce) reacts with sulfhydryl 
containing molecules under slightly alkaline conditions releasing TNB (5-thio-2-nitrobenzoic 
acid), a highly chromophoric compound with an absorbance at 412nm. The calibration curve 
is prepared by cysteine standards with a detection limit of 10 nM cysteine. 
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fig. 23 Ellman's assay: detection of SH-groups 
Dissolve 5.4 mg Ellman's reagent in 1 mL 0.1 M PBS, pH 8 and add 50 µL to 1 mL of the 
standard solutions of N-acetyl-L-cysteine (Sigma) or respectively your sample. Measure the 
absorbance of the yellow product after incubation at rt for 15 min at 412nm. The 
concentration of the sulfhydryl groups of the sample is determined by comparison to the 
standard curve. 
3.8 Immobilisation of LDH and Serum 
Different coupling methods were studied by immobilisation of LDH testing its activity when 
bound to the slides to find the most efficient immobilisation method. Furthermore rabbit 
serum immunised with PLGA-NP as well as preserum as a negative control were immobilised 
to study the interaction with PLGA-nanoparticles and the possibility of reloading. 
Organic silanised glass cover slides (3.2.2.2) were utilised for the following activations. 
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3.8.1 Cross-Linking of Two Amine-Groups 
3.8.1.1 Glutaraldehyde Activation 
Glutaraldehyde (Pentane-1,5-dial) is a homobifunctional crosslinker and one of the best and 
easiest ways to immobilise biocomponents. The disadvantage is the aging by polymerisation 
based on aldol condensation42. Crosslinking proteins can be made a point of doing but it is 
also the reason for its toxicity acting as a hapten when incorporated. Work in flue and under 
light protection. 
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fig. 24 Immobilisation of LDH with glutaraldehyde 
Add a 2.5% glutaraldehyde solution to the aminosilanised slides and shake for 1h. Wash 4x 
with ice-cold water. 
3.8.1.2 p-Chloranil Activation 
In addition to p-chloranil, also other p-halogenanils and related quinones may be in use to 
activate the amino-silanised surfaces.  
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fig. 25: Immobilisation of LDH with chloranil 
Wash the slides 2x with toluene and shake them in 1% solution of p-chloranil in toluene under 
light protection. Wash 2x with toluene, 1x with acetone and 1x with ddH2O. 
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3.8.1.3 BS3 Activation 
BS3 (bis(sulfosuccinimidyl)suberate) is a homobifunctional noncleavable crosslinker. It 
contains two sulfo-NHS ends that couple two amine-containing molecules irreversibly43. 
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fig. 26: BS3 reacts with two amine-containing molecules to form amide bond cross-links 
Dissolve 2.2 mg BS3 in 30 mL 0.1 M PBS, pH 7.2 and shake the cover slides for 2h in this 
solution. Wash 3x with buffer. 
3.8.1.4 Immobilisation of LDH onto the Activated Slides 
Dissolve 3 µL LDH (12.6 mg/ml, 643 units/mg, Sigma) in 300 µL PBS isotonic, pH 7.2. Pipet 
20 µL of this solution onto a object slide and deposit the cover slides with the activated side 
(3.8.1.1, 3.8.1.2, 3.8.1.3) on it. Incubate in a wet chamber o/n at 4°C and wash 3x with buffer. 
3.8.2 Cross-Linking Amine- With Sulfhydryl-Groups 
Sulfo-SMCC (sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate) and 
sulfo-SMPB (sulfosuccinimidyl-4-(p-maleimidophenyl)butyrate) are heterobifunctional 
crosslinkers coupling amine-containing molecules with sulfhydryl-containing ones. After 
activation of the aminosilanised slides, the split to half antibodies cleaved before with 
immobilised dihydrolipoamide (3.6.3) can be immobilised. 
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3.8.2.1 Activation with Sulfo-SMCC 
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fig. 27: Immobilisation with sulfo-SMCC 
Wash the slides with 0.1 M PBS, 15 mM NaCl, pH 7.2. Add 4.8 mg sulfo-SMCC dissolved in 
1 mL ddH2O to 15 mL of the buffer and shake the slides for 30 min in this solution. Wash the 
slides 3x with buffer. 
3.8.2.2 Sulfo-SMPB Activation 
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fig. 28: Sulfo-SMPB 
Dissolve 10 mg sulfo-SMPB in 15 mL 0.1 M PBS, pH 7.2 and shake the aminosilanised 
slides for 1 h in this solution. Wash 3x with buffer. 
3.8.2.3 Immobilisation of Half Antibodies onto the Activated Slides 
Pipet 20 µL of the split antibodies reduced with immobilised dihydrolipoamide (3.6.3) onto a 
object slide. Deposit the cover slides with the activated side (3.8.2.1, 3.8.2.2) on it. Incubate 
in a wet chamber o/n at 4°C and thereafter wash 3x with buffer. 
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3.9 Derivatisation of PLGA 
PLGA itself does not bind to gold particles. The goal of the derivatisation of PLGA was to 
introduce a free sulfhydryl group that binds covalently to the metal surface and that way to 
achieve the Gold cluster Labelling Test (3.1). 
O
O
OH
O
O
H
x y
PLGA
x - number of units of lactic acid
y - number of units of glycolic acid
≡
R OH
O
R OH
O
H2N
S
S
NH2
cystamine
EDC
R N
H
S
S
NH2
O
 
fig. 29: Derivatisation of PLGA with cystamine 
Dissolve 20 mg PLGA in 1 mL dioxane and 4 mg cystamine and 20 mg EDC in 1 mL ddH2O. 
Mix both solutions together and react for 2 h. Extract 4x with 2 mL ethyl acetate. After 
evaporating under pressure, a yellow oil will be left. 
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fig. 30: Cleaving of disulfides with DTT 
Add 5 mg dithiothreitol (DTT) to the oil. After 30 min extract with ddH2O and evaporate 
again. 
3.10 Production of PLGA-Nanoparticles44 
The NPs were produced using the water-in-oil-in-water (w/o/w) double emulsion method. 
Dissolve 400 mg polymer RG 503H (= 40 mg f-PLGA + 360 mg PLGA) in 2 g ethyl acetate 
under stirring at 4°C. Add 400 µL ddH2O or respectively your drugs if you want your 
nanoparticles medicated. Treat the solution for 60 sec with ultrasonic (sonifier, Bandelin 
electronic UW 70/HD 70; tip, MS 72/D, Berlin, Germany) under cooling by means of a water 
bath. Add rapidly 6 mL 10% Pluronic F-68 solution and treat again with ultrasonic for 50 sec 
under cooling to prepare the double emulsion. Decant the emulsion rapidly in 1% Pluronic F-
68 solution, however, avoid dropping but rather abstain from the rest of the emulsion. Stir 
with 600 U/min for 1 h at rt. Then evaporate with 170 U/min and under reduced pressure (100 
mbar) for 30 min and finally for further 30 min under absolute vacuum. Filter the suspension 
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through a micro pore filter (1µm glassfiber Prefilter, Millipore Filter). The mean size of the 
NPs and their distribution are determined by dynamic light scattering (DLS; Zetasizer Nano 
ZS, Malvern Instruments Ltd, U.K.) at 20°C. The concentration is given by the weight after 
the lyophilisation of 1 mL NP solution.  
Freezing the emulsion at -80°C keeps it stable for a very long time. For further use the NP 
solution has to be washed free from pluronic with 7x an ultra filtration membrane (Vivaflow 
50; 100000 MWCO PES, Sartorius Vivascience Gmbh) operated by a peristaltic pump (MV-
CA 8, Ismatec, Glattbrugg) at a system pressure of 2.5bar. Wash 20 mL 7x with the same 
amount of ddH2O to remove the most part of Pluronic. However, the washed NPs are less 
stable and have to be used as soon as possible. 
3.10.1 Nanoparticles Containing Alkaline Phosphatase 
After dissolving 400 mg polymer RG 503H (= 40 mg f-PLGA + 360 mg PLGA) in 2 g ethyl 
acetate under stirring at 4°C, add the alkaline phosphatase (0,02 mL, 22 mg protein/mL, 5590 
units/mg protein, Sigma-Aldrich) instead of 400 µL ddH2O to probe the NPs. The remaining 
protocol is the same like the water-in-oil-in-water (w/o/w) double emulsion method described 
above (3.10). 
A zeta-potential was measured of -36.1 mV (-26.0 mV after washing with Vivaflow50) and a 
mean diameter of 191.6 nm (167.0 nm). After washing, a concentration was determined of 9.7 
mg/mL. 
3.11  PAGE - Polyacrylamide Gel Electrophoresis 
For the SDS- and native PAGE, the Mini-ProteanII BioRad electrophoretic system was in use. 
For the different solutions of the both types of PAGEs, see below. 
Pour the separating gel and overlay with isopropanol. Remove the isopropanol after 
polymerisation has finished. Pour the stacking gel onto the separating gel and insert the 10-
slot comb. After polymerisation of the gel, remove the comb and wash the slots with running 
buffer. Fill the cathodic and anodic buffer tank with running buffer.  
The samples have to be prepared with sample buffer. Working with SDS-PAGE the sample 
has additionally to be heated 5 min at 95°C. 5-20 µL of the prepared samples are loaded into 
the slots and 2-5 µL of the protein ladder.  
The separation of the proteins occurs at 200 V and 100 mA for 45 min. 
 
 
 
  44
 
3.11.1 SDS-PAGE 
Stacking gel (4%): 
30% acrylamide/0.8% Bis   1.3 mL 
ddH2O      6.1 mL 
0.5 M Tris/HCl, pH 6.8   2.5 mL 
10% (w/v) SDS    100 µL 
10% (w/v) APS    50 µL 
TEMED     10 µL 
Separating gel (10%): 
30% acrylamide/0.8% Bis   6.7 mL 
ddH2O      8 mL 
1.5 M Tris/HCl, pH 8.8   5 mL 
10% (w/v) SDS    200 µL 
10% (w/v) APS    100 µL 
TEMED     10 µL 
Running buffer: 
Tris      3.03 g 
glycine     14.6 g 
SDS      1 g 
ddH2O      ad 1 L 
Sample buffer: 
 0.5 M Tris/HCl, pH 6.8   2.5 mL 
 20% (v/v) glycerine    2 mL 
SDS      0.4 g 
DTT      0.31 g 
bromophenol blue    1 mg 
ddH2O      ad 20 mL 
Protein ladder: 
PageRulerTM Prestained Protein Ladder, Fermentas  
(10, 17, 26, 34, 43, 55, 72, 95, 130, 170 kDa) 
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3.11.2 Native PAGE 
Stacking gel: 
30% acrylamide/0.8% Bis   1 mL 
ddH2O      4.8 mL 
0.5 M Tris/HCl, pH 6.8   2 mL 
10% (w/v) APS    80 µL 
TEMED     8 µL 
Separating gel: 
30% acrylamide/0.8% Bis   6 mL 
ddH2O      11.8 mL 
1.5 M Tris/HCl, pH 8.8   6 mL 
10% (w/v) APS    200 µL 
TEMED     20 µL 
Running buffer 
Tris      3.0 g 
glycine     14.4 g 
ddH2O      ad 1 L 
Sample buffer: 
 125 mM Tris/HCl, pH 6.8   2.5 mL 
 20% (v/v) glycerine    2 mL 
bromophenol blue    1 mg 
ddH2O      ad 10 mL 
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3.11.3 Staining of Gels with CBB-R250 
The separated proteins can be detected directly in the gel after PAGE by visualisation with 
CoomassieBrilliantBlue-R250 (CBB-R250). Incubate the gel in staining solution under 
shaking for 30 min and afterwards in destaining solution o/n. 
Staining solution: 
CBB-R250     1.25 g 
acetic acid     5 mL 
methanol     15 mL 
ddH2O      30 mL 
Destaining solution: 
acetic acid     25 mL 
methanol     60 mL 
ddH2O      ad 200 mL 
3.11.4 Drying of Gels 
To preserve the stained gel, incubate it in ddH2O with 2-5% glycerin for 10 min. Place the gel 
onto a moistened filter paper and cover with cellophane sheet carefully avoiding air bubbles. 
Dry the gel at 70°C for 2 h on a gel dryer (Slab Gel dryer CGD 4050, Savant). 
3.12  Western Blot 
Semidry-blotting (NovaBlot, Pharmacia, Multiphor II SemiDry) transfers the by PAGE (2.3) 
separated proteins from the gel to the nitrocellulose membrane. Between two graphite plates, 
the blotsandwich soaked with transfer buffer is placed free from air bubbles in following 
direction: anode/ 3 sheets of Whatman® filter paper/ gel/ nitrocellulose membrane/ 3 sheets of 
Whatman® filter paper/ cathode. 
The transfer of the proteins occurs at 10 V and 150 mA for 1.5 h. 
transfer buffer: 
Tris      5.8 g 
glycine     2.9 g 
ddH2O      ad 1 L 
adjust with 6 M HCl ad pH 6.5 
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3.12.1 Western Blot and Elisa 
After Western Blot, block the nitrocellulose membrane with blocking solution for 30min and 
wash 3x 5 min with washing solution (preparation of solutions see 3.1). Incubate the 
membrane with anti-Rabbit-IgG-ALP (1:10000 thinned in buffer) o/n and wash 3x 5 min with 
ALP-washing solution. Add the ALP-staining solution carefully; do not shake. Within 
minutes, a blue precipitate is formed where the anti-Rabbit-IgG-ALP has bound. Decant the 
ALP-staining solution and wash with ddH2O. Preparations of ALP-solutions see below. 
3.12.2 Western Blot and NP containing ALP 
After Western Blot, block the nitrocellulose membrane with blocking solution for 30 min and 
wash 3x 5 min with washing solution. Incubate the membrane with solution of nanoparticles 
containing ALP (3.10.1) o/n and wash 3x 5 min with ALP-washing solution. Add carefully 
the ALP-staining solution; do not shake. Within minutes, a blue precipitate is formed where 
the nanoparticles have bound. Decant the ALP-staining solution and wash with ddH2O. 
ALP-buffer solution, pH 9.5: 
Tris      12.11 g 
NaCl      5.84 g 
MgCl2·6H2O     20.33 g 
ddH2O      ad 1 L 
ALP-blocking solution: 
gelatine from fish skin   2 g 
Tween20     100 µL 
ALP-buffer     ad 100 mL 
ALP-washing solution:  
Tween20     100 µL 
ALP-buffer     ad 100 mL 
ALP-staining solution: 
NBT (50 mg/mL 70% DMF)   1 mL 
BCIP (50 mg/mL 70% DMF)   500 µL 
ALP-buffer     ad 50 mL 
 
  48
3.13  Determination of Titre 
PLGA-nanoparticles with a mean diameter of 200 µm and a concentration of 5.11 mg/mL 
were diluted with 50 mM carbonate buffer, pH 9.6 to a concentration of 6.25 µg/mL and 
3.125 µg/mL. Dot 100 µL of each solution in a well plate and incubate o/n at 40°C. After 
blocking for 1 h with blocking solution, wash 3x 5 min with washing solution. The sera or 
respectively the antibodies purified by PLGA-affinity chromatography (3.4.2) are diluted 
1:100, 1:500 and 1:2500. As negative controls, only buffer was used as well as the preserum. 
Add the thinned samples to the dotted nanoparticles and incubated o/n at 4°C. Wash 3x 5 min 
with washing solution and add anti-rabbit IgG-HRP 1:10000 thinned. Incubate for 2 h at rt 
and wash again 3x 5 min. Adding the substrate TMB (3,3’,5,5’-Tetramethylbenzidine, 
SCIOTEC) the colour will change to blue, measured at 370nm or 655nm. Stop the reaction 
after 15 min with 50 µL sulfuric acid. The colour changes to yellow and is measured at 
450nm. 
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4 Results and Discussions 
4.1 Biocompatible Coating 
4.1.1 Staining with OPA 
In the literature, Poly(ethylene glycol) (PEG) is one of the best described polymer for non-
fouling surfaces. By staining the biocompatible coating of slides (3.2) with the fluorescent 
molecule OPA (3.3.2), the amino groups of APTS and PEG were visualised under the 
fluorescence microscope Olympus BX41, with a resolution of 10x (N.A 0,25) and an 
exposure time of 500 ms. Thus, the success and the preferably area-wide coating should be 
examined. The different coupling methods were studied under several pH conditions. 
Following (coated) slides were studied by means of OPA: 
I. uncoated slides as negative control (no amino groups) 
 
fig. 31 Uncoated slides 
II. slides coated with APTS, organic solvent deposition (3.2.2.2) 
 
fig. 32 Aminosilanisation, organic deposition 
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III. slides coated with APTS, aqueous deposition (3.2.2.2) 
 
fig. 33 Aminosilanisation, aqueous deposition 
IV. IgG-HRP was cleaved with immobilised dihydrolipoamide (3.6.3). The splitted 
antibodies were immobilised onto the slides coated with APTS, organic deposition 
(3.2.2.2), via the sulfhydryl groups in the hinge region reacting with OPA.  
 
fig. 34 IgG-HRP splitted and immobilised onto aminosilanised slides 
 Adding the substrate TMB (2.2.2.2) a blue staining was observed, too (4.1.2). 
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V. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 6 (3.2.3) 
 
fig. 35 Succinic anhydride, pH 6 
VI. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 8.4 (3.2.3) 
 
fig. 36 Succinic anhydride, pH 8.4 
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VII. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH6 (3.2.3) 
• EDC, pH 6 (3.2.4) 
• bisamino-PEG in 50 mL carbonate-bicarbonate buffer, pH 5 (3.2.5) 
 
fig. 37 Pegylation 
VIII. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH6 (3.2.3) 
• EDC, pH 6 (3.2.4) 
• bisamino-PEG in 50 mL carbonate-bicarbonate buffer, pH 5 (3.2.5) 
• splitted IgG-HRP (3.6.3) immobilised via its sulfhydryl groups in the hinge 
region reacting with OPA 
 
fig. 38 Splitted IgG-HRP immobilised onto pegylated slides 
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IX. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH6 (3.2.3) 
• EDC and sulfo-NHS, pH 6 (3.2.4) 
• bisamino-PEG in 50 mL carbonate-bicarbonate buffer, pH 5 (3.2.5) 
 
fig. 39 Pegylation 
X. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH6 (3.2.3) 
• EDC and sulfo-NHS, pH 6 (3.2.4) 
• bisamino-PEG in 50 mL carbonate-bicarbonate buffer, pH 5 (3.2.5)  
• splitted IgG-HRP (3.6.3) immobilised via its sulfhydryl groups in the hinge 
region reacting with OPA 
 
fig. 40 Splitted IgG-HRP immobilised onto pegylated slides 
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XI. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH6 (3.2.3) 
• EDC, pH 8 (3.2.4) 
• bisamino-PEG in 50 mL carbonate-bicarbonate buffer, pH 8 (3.2.5) 
 
fig. 41 Pegylation 
XII. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 6 (3.2.3) 
• EDC, pH 10 (3.2.4) 
• bisamino-PEG in 50 mL carbonate-bicarbonate buffer, pH 8 (3.2.5) 
 
fig. 42 Pegylation 
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XIII. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 8.4 (3.2.3) 
• EDC, pH 8 (3.2.4) 
• bisamino-PEG in 50 mL carbonate-bicarbonate buffer, pH 8 (3.2.5) 
 
fig. 43 Pegylation 
XIV. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 8.4 (3.2.3) 
• EDC, pH 10 (3.2.4) 
• bisamino-PEG in 50 mL carbonate-bicarbonate buffer, pH 8 (3.2.5) 
 
fig. 44 Pegylation 
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XV. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 8.4 (3.2.3) 
• EDC, pH 10 (3.2.4) 
• bisamino-PEG in 50 mL carbonate-bicarbonate buffer, pH 10 (3.2.5) 
 
fig. 45 Pegylation 
XVI. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4M succinic anhydride solution in 50 mM PBS, pH 8.4 (3.2.3) 
• EDC, pH 8 (3.2.4) 
• bisamino-PEG in 50 mL carbonate-bicarbonate buffer, pH 10 (3.2.5) 
 
fig. 46 Pegylation 
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XVII. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 8.4 (3.2.3) 
• EDC, pH 10 (3.2.4) 
• bisamino-PEG in 50 mL carbonate-bicarbonate buffer, pH 10 (3.2.5) 
• splitted IgG-HRP (3.6.3) immobilised via its sulfhydryl groups in the hinge 
region reacting with OPA 
 
fig. 47 Splitted IgG-HRP immobilised onto pegylated slides 
XVIII. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 8.4 (3.2.3) 
• EDC and sulfo-NHS, pH 10 (3.2.4.1) 
• bisamino-PEG in 50 mL carbonate-bicarbonate buffer, pH 10 (3.2.5) 
 
fig. 48 Pegylation 
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XIX. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 8.4 (3.2.3) 
• EDC and sulfo-NHS, pH10 (3.2.4) 
• bisamino-PEG in citric acid-sodiumcitrate buffer, pH 5 (3.2.5) 
• splitted IgG-HRP (3.6.3) immobilised via its sulfhydryl groups in the hinge 
region reacting with OPA 
 
fig. 49 Splitted IgG-HRP immobilised onto pegylated slides 
XX. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 8.4 (3.2.3) 
• EDC and sulfo-NHS, pH 10 (3.2.4) 
• bisamino-PEG in carbonate-bicarbonate buffer, pH 10 (3.2.5) 
• splitted IgG-HRP (3.6.3) immobilised via its sulfhydryl groups in the hinge 
region reacting with OPA 
 
fig. 50 Splitted IgG-HRP immobilised onto pegylated slides 
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XXI. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 8.4 (3.2.3) 
• EDC, pH 6 (3.2.4) 
• bisamino-PEG in carbonate-bicarbonate buffer, pH 10 (3.2.5) 
• splitted IgG-HRP (3.6.3) immobilised via its sulfhydryl groups in the hinge 
region reacting with OPA 
 
fig. 51 Splitted IgG-HRP immobilised onto pegylated slides 
XXII. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 8.4 (3.2.3) 
• EDC, pH10 (3.2.4) 
• bisamino-PEG in carbonate-bicarbonate buffer, pH 10 (3.2.5) 
• splitted IgG-HRP (3.6.3) immobilised via its sulfhydryl groups in the hinge 
region reacting with OPA 
 
fig. 52 Splitted IgG-HRP immobilised onto pegylated slides 
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XXIII. slides coated with  
• APTS, organic deposition (3.2.2.2) 
• 0.4 M succinic anhydride solution in 50 mM PBS, pH 8.4 (3.2.3) 
• EDC, pH 10 (3.2.4) 
• amino-methoxy-PEG (CH3(OCH2CH2)nNH2) in 50 mL carbonate-bicarbonate 
buffer, pH 10 (3.2.5) instead of bisamino-PEG 
 
fig. 53 Pegylation with methoxy-PEG 
XXIV. Coupling with chloranil (3.8.1.2) interferes under the fluorescent microscope. 
This coupling method was further studied by immobilisation of LDH (4.1.3) 
 
The aminosilanisation with organic (I) and aqueous (II) deposition are approximate. However, 
the aminosilanisation by organic deposition is a more simple and faster method, thus it was 
preferred for the further coatings. 
Coupling of splitted IgG-HRP via its sulfhydryl groups in the hinge region onto 
aminosilanised slides by means of OPA (III) shows a positive signal proving that the 
immobilisation of antibody onto aminosilanised slides is done successfully as well as the 
previous splitting of antibodies with immobilised dihydrolipoamide (3.6.3). 
After coating with succinic anhydride under the condition of pH 8.4 (VI) a signal is no longer 
observable. By coupling of succinic anhydride with pH 6 (V), the signal decreases also in 
contrast to aminosilanised slides but not that much as (VI). Higher pH results in more 
positively charged amino groups, thus the reaction occurs more effectively and these 
conditions are preferable. 
The comparison of pegylation by means of EDC (VII, XI, XII, XIII, XIV, XV, XVI, XXI) 
under different pH conditions is difficult, as the unbound amino group of bisamino-PEG is 
not only straightened outward, but PEG also forms coils or both amino ends can be bound via 
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EDC. However, coupling of bisamino-PEG with EDC and sulfo-NHS (IX, XVIII) shows an 
unique coating signal, which reconfirms that sulfo-NHS significantly increases the reaction 
yield. The coupling of bisamino-PEG in alkaline solution (pH 10) seems to be more 
successfully than in acid solution (pH 5), so this method was preferred for further 
immobilisations. 
The immobilisation of splitted IgG-HRP via its sulfhydryl groups in the hinge region onto 
pegylated slides by means of OPA is successfully for both bisamino-PEG coupled only with 
EDC and bisamino-PEG coupled with EDC and sulfo-NHS. This is also important for the 
further immobilisation of PLGA-Ab onto the biocompatible coating of medical relevant 
materials with regard to drug-targeting and drug-reloading. 
The last picture (XXIII) shows amino-methoxy-PEG coupled with EDC. This was done as a 
negative control where no amino groups are available on the surface. An effective coating 
with PEG is pointed out with it. 
4.1.2 Staining with TNBS 
Following slides were stained with TNBS (3.3.1): 
• slides after organic solvent deposition (3.2.2.2) 
• slides after aqueous deposition (3.2.2.1) 
• slides after pegylation in carbonate-bicarbonate buffer, pH 10 (3.2.5) 
• slides after pegylation in citric acid-sodium citrate buffer, pH 5 (3.2.5) 
Add 1 mL 10% SDS and 0.5 mL 1 M HCl to each sample. 
A faint yellow staining was observed on the slides after organic deposition. 
4.1.3 Activity Measurement of Immobilised Lactate Dehydrogenase (LDH) 
L-Lactate dehydrogenase ((S)-Lactate: NAD+ oxidoreductase, E.C. 1.1.1.27) catalyses the 
redox reaction from pyruvate and NADH/H+ to (S)-lactate and NAD+ with a turn over rate of 
14000 min-1 (pyruvate + NADH)45 (fig. 54) and its reverse reaction. The pH optimum ranges 
between pH 6 and pH 8. 
LDH is an ubiquitous enzyme among all vertebrates. It catalyzes the final reaction of 
glycolysis, the formation of L-(+)-lactic acid. The enzyme activity found in serum or plasma 
usually originates from liver, heart, skeletal muscle erythrocytes and tumours. (...) To obtain 
serum samples (...) large haemolysis must be prevented in any case46. LDH is a tetrameric 
molecule with five isoenzymes found in humans. The concentration of LDH in serum is used 
as clinical laboratory parameter e.g. for indication of myocardial infarction. 
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fig. 54 LDH catalyses the redox reaction from pyruvate and NADH/H+ to (S)-lactate and NAD+ 
The subunits of LDH have a molecular weight of 36000. This molecular weight was found in 
SDS-PAGE, too, for the rabbit serum as well as for the serum purified with affinity 
chromatography. This suggested the conclusion that LDH binds via its active site to PLGA-
nanoparticles. 
Coupling methods with chloranil and glutaraldehyde were used to immobilise lactate 
dehydrogenase (LDH, 5 mg/mL, Roche) onto aminosilanised slides, organic deposition 
(3.2.2.2), and the activity of the immobilised enzyme was measured in a long-term test. 
Immobilising LDH, different orientations of the active site are possible. Hence, some samples 
of the enzyme were first incubated with PLGA-NP o/n at 4°C to block the active site. 
Coupling then the LDH-nanoparticle complex onto the carrier material, the active site is 
adjusted outwards due to the sterical hindrance (fig. 55). 
 
fig. 55 Immobilisation and orientation of LDH 
In the group, Haifa Al-Dubai and Martina Strobl further investigated the interactions with 
PLGA-NP of bound LDH and purified (PLGA-)antibodies from serum. 
4.1.3.1 Standard Curve 
Solution for maximum activity: 
  isotonic PBS-buffer, pH 7.3  1.4 mL 
  pyruvate (8.28 µmol/mL)  50 µL 
  NADH (0.233 µmol/mL)  25 µL 
  LDH (different concentrations) 35 µL 
The absorbance was measured after 1 min at 339nm against a blank value. 
carrier material 
covalent bound 
LDH 
PLGA-NP 
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fig. 56 standard curve of LDH activity measurement 
4.1.3.2 Activity Measurement of Immobilised LDH 
The immobilisation methods are described in (3.8). Following methods were investigated: 
LDH immobilised with 
• chloranil (LDH Cl) 
• chloranil and afterwards incubated with PLGA-NP (LDH Cl Nano) 
• chloranil and afterwards incubated with HSA (LDH Cl HSA) 
• glutaraldehyde (LDH GA) 
• glutaraldehyde and afterwards incubated with PLGA-NP (LDH GA Nano) 
• glutaraldehyde and afterwards incubated with HSA (LDH GA HSA) 
LDH previously incubated o/n at 4°C with PLGA-NP and afterwards immobilised with 
• chloranil (LDH + Nano Cl) 
• glutaraldehyde (LDH + Nano GA) 
The slides were shaken in 1.5 mL of following solution 
  isotonic PBS-buffer, pH 7.3  1.435 mL 
  pyruvate (8.28 µmol/mL)  50 µL 
  NADH (0.233 µmol/mL)  25 µL 
and the activity was measured in a long-term test. 
A measurable activity is only observable with LDH previously incubated with PLGA-NPs 
(fig. 57). This reconfirms that LDH binds via its active site to PLGA-NP, because the active 
site is oriented outward and an activity can be measured. Thereby, the coupling method with 
glutaraldehyde is about twice as effective as the coupling method with chloranil. 
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fig. 57 Activity measurement of immobilised LDH 
An idea of this result that LDH binds to PLGA-NP was also to use immobilised LDH for 
drug-targeting and drug-reloading, but the interaction between LDH and the nanoparticles is 
too weak for effective drug-targeting. 
However, this experiment demonstrated the importance to block previously the active site of 
the enzyme (as well as the cognitive domains of antibodies) before immobilisation to obtain 
the most effective orientations. 
4.2 Gold Cluster Labelling Test 
4.2.1 Stability Check of GCC Solution 
The gold cluster colloid solution (3.1) shows an absorbance maximum at 520nm. Adding 
electrolytes like sodium chloride to the GCC solution leads to coagulation. However, the 
spontaneous absorption of proteins (in this case tested with 1 µL BSA-antibody) stabilise 
already the GCC measurable by the decrease of the absorbance maximum. Blocking with 
agents such as 1% fish gelatine (FG) stabilise additionally and prevents coagulation adding 
then electrolytes. 
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fig. 58 stability check of GCC solution 
4.2.2 Pretests 
As pretests for determination of titre, 2 µL PLGA solutions (5, 2.5, 1, 0.5, 0.1, 0.05 mg 
PLGA/mL) were dotted onto nitrocellulose membrane and the membrane was blocked and 
washed thereafter. 
The GCC were labelled with: 
• preserum 
• serum of rabbit H52 
• serum of rabbit H53 
• serum of rabbit H52 purified with PLGA-affinity chromatography  
Proteins in the sera labelled on gold cluster colloids bind to the dotted PLGA (fig. 59). With 
this experiment, the interactions between serum proteins and PLGA were visualised. However, 
several immunoglobulins as well as albumins and other serum proteins bind unspecifically to 
PLGA. 
With the serum of rabbit H52 purified with PLGA-affinity chromatography, no signal was 
observable. This is may be a question of the concentrations. 
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fig. 59 Gold Cluster Labelling Test with serum labelled on GCC and with dotted PLGA 
For signal amplification, the Gold Cluster Labelling Test was conducted with protein G, 
which binds with high affinity to the Fc fragment of IgG (and with a weak binding to 
albumins). The GCC were first labelled with protein G (1 - 5 µL) and thereafter with the same 
amount of serum (fig. 60). As negative control a GCC solution only with protein G and 
blocked was used. 
 
fig. 60 signal amplification with protein G 
The signal decreases by the decrease of the PLGA concentration dotted (2 µL of 5 – 0.05 
mg/mL) as well as by the decrease of serum labelled to the GCC (5 – 1 µL). This reconfirms 
the interaction between serum proteins and PLGA. However to determine the kind of proteins 
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and whether (PLGA-)antibodies or not, ELISA with the secondary antibody anti-Rabbit-IgG 
(4.5.3.1) was conducted. 
4.2.3 Gold Cluster Labelling Test with Modified PLGA 
For preparation of the solutions and the standard operation procedure of the Gold Cluster 
Labelling Test see (3.1). 
a) Dotting: 
Following probes were dotted onto nitrocellulose membrane, each with 1 µL:  
• LDH (1:100 diluted),  
• HSA (50 µg/mL),  
• BSA (50 µg/mL),  
• sera,  
• sera after affinity chromatography (3.4.2) 
• the flow of the affinity chromatography 
• PLGA (3 mg/ml dioxane) 
• NADH 
Dry for 1h at rt. After blocking with blocking solution, wash 3x5min with washing solution 
and 3x with ddH2O.  
b) Gold cluster labelling of modified PLGA 
Add 1 µL modified PLGA (3.9) (1:100 diluted) to 10 mL gold cluster solution and shake for 
30 min. Block with blocking (1% fish gelatine in ddH2O) solution for 15 min. As negative 
controls 2 µL PLGA (3mg/ml dioxane) were used instead of modified PLGA and gold cluster 
solution only blocked. 
Incubate the dotted probes with the labelled gold cluster solutions for 2h. Wash 3x 5min with 
washing solution. 
However, no relevant signal was observed with modified PLGA labelled GCC in comparison 
to the negative control of blocked GCC. 
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4.3 Bradford Protein Assay 
standard curve 
50 µL of the sample were added to 2.5 mL Bio-Rad Protein Assay (1:5 diluted) and the 
absorbance was measured after 10 min at 595nm against a blank value. 
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fig. 61 Bradford Protein Assay – standard curve 
4.4 Ellman's Assay 
standard curve 
To 1 mL of the standard solution of N-Acetyl-L-Cystein 50 µL Ellman's Reagent (5.4 mg/mL 
0.1 M PBS, pH8) were added and the absorbance was measured after 15 min at 412nm 
against a blank value. 
y = 0,002x + 1,416
R² = 0,986
1,41
1,42
1,43
1,44
1,45
1,46
1,47
1,48
1,49
1,50
1,51
1,52
0 10 20 30 40
A 
(1
5m
in
)
c (N-Acetyl-L-Cystein) [µmol/mL]
  
fig. 62 Ellman's Assay – standard curve 
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4.5 Purification and Verification of PLGA-Ab 
4.5.1 Determination of Titre 
For determination of the titre, different amounts of PLGA-NP (final amount of 6.25 µg and 
3.125 µg) were dotted into micro wells and the wells thereafter blocked and washed. Sera 
1:100, 1:500 and 1:2500 diluted were incubated and the bound IgG was detected with anti-
rabbit-IgG-HRP and stained with TMB (fig. 63, fig. 64). 
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 fig. 63 Determination of titre (with 6.25 µg PLGA dotted)  
The absorbance decreases. Thus, IgG bind to the dotted PLGA, but no relevant titre is 
observable in comparison with preserum. It is known that several immunoglobulins bind 
unspecifically to PLGA-NP. 
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fig. 64 Determination of titre (with 3.125 µg PLGA dotted) 
The same procedure only with 3.125 µg PLGA dotted, but also no relevant titre is observable. 
Rather at serum of rabbit H52 a titre is determined than the other ones, which would agree 
with other experiments like Western Blot and ELISA (4.5.3.1). 
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4.5.2 Polyacrylamide Gel Electrophoresis 
4.5.2.1 SDS PAGE 
Following samples were separated with the aid of SDS-PAGE (3.11.1): 
(1) preserum (as negative control) 
(2) serum of rabbit H52 immunised with PLGA-NP 
(3) serum of rabbit H53 immunised with PLGA-NP 
(4) serum of rabbit H52 immunised with PLGA-NP and purified with PLGA-affinity 
chromatography. Therefrom was loaded onto the gel: 
a. flow of the serum, which was not bound by the affinity chromatography 
b. eluate 
(5) the samples marked with Haifa are from serum of rabbit H52 immunised with PLGA-
NP and purified with different chromatographic methods conducted by Haifa Al-
Dubai 
 
fig. 65 SDS-PAGE 
The gel was stained with CBB. All samples show a signal with a molecular weight of about 
36000 to 38000. This suggested the conclusion of LDH (for that purpose see 4.1.3). 
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4.5.2.2 Native PAGE 
Following samples were separated with the aid of native PAGE (2.3.3): 
(1) serum of rabbit H52 immunised with PLGA-NP 
(2) serum of rabbit H53 immunised with PLGA-NP 
(3) preserum 
(4) serum of rabbit H52 immunised with PLGA-NP and purified with PLGA-affinity 
chromatography. Therefrom was loaded onto the gel 
a. eluate 
b. flow of the serum, which was not bound by the affinity chromatography 
c. eluate 
(5) preserum purified with PLGA-affinity chromatography (as negative control). 
Therefrom was loaded onto the gel 
a. flow of the serum, which was not bound by the affinity chromatography 
b. eluate 
(6) serum of rabbit H52 immunised with PLGA-NP and purified with proteinA-affinity 
chromatography, conducted by Haifa Al-Dubai 
 
fig. 66 native PAGE 
The gel was stained with CBB. No bands are visible at the eluates both H52 and preserum. 
The affinity chromatography was conducted with only 100 µL serum to purify PLGA-
antibodies, thus the concentration is too low for staining with CBB. Hence, Western Blot 
(4.5.3) with the same samples was accomplished to detect then with the more sensitive ELISA. 
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4.5.3 Western Blot 
After separating the proteins with native PAGE (4.5.2.2), the proteins were transferred onto a 
nitrocellulose membrane with Western Blot. The proteins were detected by ELISA and by 
PLGA-NP containing ALP. 
4.5.3.1 Western Blot und Elisa anti-Rabbit IgG-ALP 
The blotted proteins were detected with anti-rabbit-IgG-ALP (3.12.1). 
 
fig. 67 Western Blot and Elisa anti-rabbit IgG-ALP 
Staining with BCIP and NBT, IgGs were detected in the eluate. However, immunoglobulins 
bind also unspecifically to PLGA-NP. For future perspectives, the purification of immunised 
rabbit serum has to be done with higher concentrations and the antibodies have to be verified 
afterwards with mass spectroscopy to determine if PLGA-Ab or not. 
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4.5.3.2 Western Blot and PLGA-NP containing ALP 
The blotted proteins were incubated with a solution of PLGA-NP containing ALP (3.12.2). 
 
fig. 68 Western Blot and NP containing ALP 
Staining with BCIP and NBT shows several bands visible at serum samples as well as one 
band in the flow, which is in the range of albumins. This reconfirms the interaction between 
albumins and PLGA-NP, which is a main limitation of drug targeting (see introduction). 
The eluate shows no visible band. However, IgG purified with PLGA-affinity 
chromatography was detected with ELISA on Western Blot. Thus, the detection with PLGA-
NP containing ALP is not sensitive enough and the method has to repeated with higher serum 
concentrations. 
As negative control a Western Blot with the same types of samples was shaken in ALP-
staining solution, however, no staining was observed. 
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5 Summary and Future Perspectives 
The main focus of this master thesis was based on biocompatible coatings of medically 
relevant materials and its verification as well as on the purification of PLGA-antibodies from 
sera and its detection by titre determination, PAGE and Western Blot. 
Biocompatible coating was studied by staining with the fluorescent molecule OPA. By this 
method, the immobilisation of splitted antibodies could also be shown. By immobilisation of 
LDH onto aminosilanised slides, the importance to block previously the active site was 
demonstrated to obtain the most efficient orientation of the enzyme (and of antibodies). 
Sera of the immunised rabbits H52 and H53 were purified with PLGA-affinity 
chromatography. By the determination of titre, no relevant titre was observed in comparison 
to preserum. However, the detection of IgG with Western Blot and Elisa was successful, 
primary with the serum of rabbit H52. This might derive from the fact that also additives 
giving during the course of immunisation cause IgG production specific to their surface 
structure. Eventually, the same procedure should be done with higher concentrations, means 
with more serum to purify the (PLGA-)antibodies. 
After working on my master thesis, another two rabbits were immunised. With these sera, the 
titre determination seemed to be more successfully. 
It is known, that immunoglobulins bind unspecific to PLGA-NP. Therefore the next step is 
the identification of the separated immunoglobulins IgG by means of mass spectrometry. If 
antibodies specific to PLGA-NPs can be identified, a monoclonal antibody has to be cloned 
and the experiments of drug-targeting and drug-reloading have to be repeated with it. 
The experiments of drug-targeting and drug-reloading in a long-term experiment were 
accomplished by Haifa Al-Dubai and show great promise. 
In spite of all troubles, the project seems to succeed! 
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5.1 Summary and Future Perspectives (German) 
Der Schwerpunkt dieser Diplomarbeit lag, neben der biokompatiblen Beschichtung 
medizinisch relevanter Materialien und deren Verifizierung, auf der Reinigung von PLGA-
Antikörpern aus Seren und deren Nachweis mittels Titerbestimmung, PAGE und Western 
Blot. 
Die Untersuchung der biokompatiblen Beschichtung erfolgte mit Hilfe des 
Fluoreszenzmoleküls OPA. Damit konnte auch die Immobilisierung gespaltener Antikörper 
gezeigt werden. Bei der Immobilisierung von LDH auf aminosilanisierten Deckgläsern wurde 
die Bedeutung aufgezeigt, die Aktivitätsstelle vorher zu blocken, um eine möglichst effektive 
Orientierung von Enzymen (und auch von Antikörpern) zu erhalten. 
Die Seren von den immunisierten Kaninchen H52 und H53 wurden mittels PLGA-
Affinitätschromatographie gereinigt. Bei der Titerbestimmung war jedoch im Vergleich zum 
Präserum kein relevanter Titer bestimmbar. Der Nachweis von IgG mit Western Blot und 
Elisa war jedoch positiv, insbesondere beim Serum vom Kaninchen H52. Dies kann von der 
Bildung von IgG´s gegen die verschiedenen Additive, die bei der Immunisierung verwendet 
wurden, kommen. Eventuell sollten die Versuche mit höheren Konzentrationen, sprich mit 
mehr gereinigtem Serum, nochmals durchgeführt werden. 
Nach der praktischen Arbeit an meiner Diplomarbeit wurden zwei neue Kaninchen 
immunisiert. Bei diesen schien die Titerbestimmung erfolgreicher zu sein. 
Es ist bekannt, daß Immunglobuline unspezifisch an PLGA-NP binden. Deshalb wäre der 
nächste Schritt die Identifizierung der gereinigten Immunglobuline IgG mittels 
Massenspektrometrie. Falls Antikörper spezifisch gegen PLGA-NP nachgewiesen werden 
können, müßten daraus monoklonale Antikörper hergestellt werden und die Versuche drug-
targeting und drug-reloading damit wiederholt werden. 
Die Experimente für drug-targeting und drug-reloading in einem Langzeitversuch wurden 
von Haifa Al-Dubai durchgeführt und sind vielversprechend. 
Trotz aller Schwierigkeiten ist das Projekt erfolgreich! 
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CHAPTER II: DEVELOPMENT OF AN ALLERGY TEST 
Abstract 
An in vitro allergy test in microtitre plates was developed in the working group of Professor 
Pittner by means of Gold Cluster Labelling Test (2.2.3). The detection of the allergen occurs 
by gold cluster colloids labelled with the serum of the patient, which contains IgE specific to 
the proteins the patient is allergic to. 
The advantages over commonly used ELSA tests are the inexpensive and simple application 
and the colour stability for long-term documentation as well as no hazardous reagents are 
necessary. The GCC Labelling Test can be also made as kits and the application of ELISA 
reader makes automation possible. Thereby the sensitivity of this test is comparable to ELISA 
techniques. 
Abstract (German) 
Ein in vitro Allergentest in Mikrotiterplattenformat mittels Goldcluster Labelling Test wurde 
in der Arbeitsgruppe von Professor Pittner entwickelt. Der Nachweis der Allergene erfolgte 
mit Goldcluster-gelabeltem Serum von Allergikern. Dieses enthält IgE spezifisch gegen das 
nachzuweisende Allergen. 
Der Vorteil gegenüber herkömmlich genutzten ELISA Tests sind die kostengünstige und 
einfache Handhabung und die Farbstabilität für Langzeitdokumentation. Außerdem sind keine 
gefährlichen Reagentien nötig. Der GCC Labelling Test kann auch als Kit gestaltet werden 
und durch Anwendung von ELISA Readern ist eine Automatisierung möglich. Die 
Sensitivität dieses Tests ist dabei vergleichbar mit denen von ELISA. 
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1 Introduction 
1.1 Allergy 
Allergies are an inadequate and an enhanced immune reaction concerning normally harmless 
substances. Characteristic features are47: 
• allergy develops only after several contacts with the allergen 
• only a part of humans, who are in contact with the allergen, fall ill 
• the immunoglobulin IgE is involved 
• mast cells release active agents (mediators) 
The most allergy-causing substances are proteins (antigens) elicited inter alia by mite, pollen, 
fungi, domestic animal hairs, stinger, chemical substances, medicaments and food. The 
question when does a protein become an allergen? is reviewed by Mari A. and for further 
information be referred on it. Important is the Evaluation of the IgE reactivity of naturally 
purified molecule within a general population, in one or more geographical areas (...). 
Defining the symptomatic/asymptomatic ratio48. 
The "classical" allergy is one of the four forms of hypersensitivity (type I – IV) and called type 
I (immediate hypersensitivity, IgE-mediated). More than 20% of persons in industrialised 
countries are affected. 
During the first contact with an allergen, the immunopathogenic key processes are49: 
• the activation of TH2-cells with an increased production of the cytokines IL-4, IL-5, 
IL-9 and IL-13 
• the differentiation (class switching) to IgE or respectively IgG1 expressing B-cells 
• the production of these immunoglobulins through plasma cells 
• binding of IgE via high affine Fc receptors (FcεRI) on the surface of mast cells (about 
300000 IgE per cell) and of basophil granulocytes. Mast cells are located with a high 
density in mucosae. 
In a second contact, the immunoglobulins IgE bound on the surface of mast cells are 
crosslinked by the allergen. Thus, the granula changes and the mast cell degranulates and 
releases mediators such as histamine. Each mast cell contains up to 5 pg histamines, a 
vasoactive amine that cause the anaphylactic reactions and the undesirable symptoms of an 
allergy (e.g. asthma or allergic rhinitis). In a later secondary reaction, activated mast cells set 
free cytokines, which affect inflammatory with a dead time of 5 to 6 hours. The stages of the 
first and second contact leading in the end to the release of histamine are shown in (fig. 69). 
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fig. 69 First contact: production of IgE by activation of TH2 and class switching of B-cells; second contact: 
releasing of histamine caused by crosslinking of IgE bound on the surface of the mast cells. In comparison 
to it: the pseudo-allergy to the right. 
From allergy are to differentiate pseudo-allergy and intolerance. Certain substances (pseudo-
allergens) act directly on the degranulation of mast cells and thus effect the release of 
histamine (fig. 69) with symptoms similar to the allergic ones. However, the intolerance is 
based on metabolic disorders, mostly caused by enzyme deficiency (e.g. lactose intolerance). 
The cross-reactivity of IgE is not only of interests by patients, who mostly react to more than 
a single allergen, but also for the development of an allergy test. Cross-reactivity has a clear 
structural basis: no relevant cross-reactivity without structural similarity. For globular 
proteins (i.e., for most allergens), structural similarity requires similarity in folding50. 
The increased IgE level of allergic persons is measured in vitro allergy tests. 
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1.2 Allergy tests 
Tests for the allergen, which causes the allergic response, can be made by: 
• skin tests: small amounts of possible allergens are placed on or below the skin. After 
20 min, the reaction (wheal development) is compared with a positive control 
(histamine) and a negative control (agent-free). 
o skin prick test: one of the most commonly used allergy test. Suspected 
allergens are dropped on the skin and with little scratches allowed to enter the 
skin. 
• elimination tests: used to check food allergy.  
o In a diet, foods with possible allergens are avoided for several weeks. 
Afterwards, they are administered again under medical control looking at 
possible symptoms.  
o Another possibility is a double-blind study giving foods and harmless 
substances in a disguised form. 
• blood tests: measuring of the IgE concentration in serum. Thereby, the free IgE as a 
whole or the allergen-specific IgE can be determined. Commonly used methods are: 
o fluoro immunoassay (FIA) 
o enzyme-linked immunosorbent assay (EIA, ELISA) 
o radioallergosorbent test (RAST) 
o radioimmunosorbent test (RIST) 
The principle of the immunoassays are described in (2.2). 
The skin test is a rapid, inexpensive test but cannot carry out with patients having hives or 
eczema. Another obstacle is taking medicine such as antihistamines, which falsify the result 
by preventing or reducing the allergic reaction. Reacts the person allergic to several allergens 
e.g. in food allergy, the main allergen can be found out with in vitro tests. Above all, a blood 
test has to be done instead of a skin test at patients with a high risk of anaphylaxis. 
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2 Methods and Experimental Section 
2.1 Cohn-Fractionation of Blood Plasma 
The plasma fractionation is used to separate and purify proteins from blood. Thereby the 
different solubility concerning pH, temperature, ionic strength, behaviour in solvents and 
interactions with solid phases is utilised. 
Slowly unfreezing deep-frozen plasma to about 1°C, blood coagulation factors remain 
insoluble and are centrifuged to obtain the cryoprecipitate. The serum contains about 70 
mg/mL proteins therefrom 12 mg/mL γ-globulins. The percentage of immunoglobulins with 
17% is relatively low in contrast to albumins with 63.7%51. 
The proteins in the cryo-poor plasma are further separated by fractionation with increasing 
concentrations of ethanol and a temperature below 0°C, established by Edwin Joseph Cohn 
(1892-1953):  
If alcohol precipitation is carried out at sufficiently low temperature (close to -5°C), 
denaturation is often prevented. (...) Alcohol precipitation methods (...) have the decided 
advantage that precipitates from ethanol-water mixtures at low temperatures can be readily 
dried under vacuum. This yields solid, salt-free, water-soluble, purified proteins52. 
The principle of the plasma fractionation is shown in (fig. 70). 
 
fig. 70 Plasma fractionation 
unfreeze and centrifugation 
cryo-poor plasma 
8% ethanol-precipitation, 
-3°C, centrifugation 
cryoprecipitate 
25% ethanol-precipitation, 
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fraction IV 
albumins 
fraction II + III 
immunoglobulins 
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deep-frozen blood plasma 
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After separation of fraction I by 8% ethanol-precipitation, immunoglobulins are precipitated 
with 20-25% ethanol and centrifuged. The last step with 40% ethanol yields albumins with 
the highest solubility and lowest isoelectric point of the plasma proteins. The separated 
fractions can be further purified e.g. by chromatographic methods to obtain the desired 
proteins. 
2.2 Cohn-Fractionation 
Unfreeze slowly 1 mL deep-frozen blood plasma of an allergic person to about 1°C. The 
sample is centrifuged in a cold room for 10 min at 14000 rpm. The cryoprecipitate is removed. 
Add ethanol to the cryo-poor supernatant (final concentration 8%). Cool down to about -3°C 
and centrifuge for 15 min at 14000 rpm and with a temperature of -3°C. The pellet is removed 
and ethanol is added to the supernatant to obtain a final concentration of 25% ethanol. Cool 
down again under 0°C and centrifuge for 15 min at 14000 rpm and -3°C. 
A part of the ethanol can be removed from the precipitates by speed vacuum, however avoid a 
complete dehydration, which would denature the proteins. 
The precipitates were dissolved in 500 µL ddH2O and a Gold Cluster Labelling Test (2.2.3, 
3.1) was conducted. 
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3 Results and Discussion 
3.1 ELISA to Recheck the Cohn-Fractionation 
The detection of IgG in the Cohn-fractions was accomplished by ELISA. 
100 µL of the fractions were incubated in a wet chamber o/n at 4°C in micro wells. After 
blocking for 30 min with blocking solution (0.1% BSA/0.1% Tween20/PBS, pH 7.2), wash 
3x 5 min with washing solution (0.5% Tween20/PBS). Incubate with 100 µL anti-human-
IgG-HRP (SB2D40-05, #C248-X549J) for 2 h in a wet chamber at rt. Wash 3x 5min with 
washing solution and stain thereafter with a TMB-solution (SCIOTEC). 
 
fig. 71 ELISA to recheck the Cohn-fractionation (prec. = precipitation, supernat. = supernatant) 
The most IgG were found in the fraction with 25% ethanol precipitation, which reconfirms 
the blood plasma fractionation, but also in the fractions before immunoglobulins could be 
detected. 
3.2 Allergy Test in vitro 
The sera of allergic persons were obtained from the company SCIOTEC. With the serum of 
the patient 199439, who is allergic against grasses, birch trees and house dust mites, a Cohn-
fractionation was conducted. 
From Allergopharma Vertriebsges.mbH., Vienna, the Prick-/Scratch testing solutions (3.0 mL) 
were received. Following samples were dotted into micro wells: 
1) 708 dermatophagoides farinae (130 µg/mL) (dust mite, Ed.) 
2) 725 dermatophagoides pteronyssinus (standardised concerning biological activity) 
(house dust mite, Ed.) 
3) 044 fungi I (380 µg protein/mL) 
4) 106 mugwort (standardised concerning biological activity) 
5) 116 ash tree (320 µg/mL) 
6) 108 birch tree (standardised concerning biological activity) 
7) 154 short ragweed (320 µg/ml)  
8) 006 grasses (standardised concerning biological activity) 
9) 015 grasses/cereals (630 µg/ml) 
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Following samples were additionally dotted: 
10) HSA (1 mg/mL) 
11) BSA (1 mg/mL) 
12) PLGA (2 mg/mL PLGA) 
Following fractions of the Cohn-fractionation of the serum 199439 were labelled to GCC: 
A) cyro precipitate (blood coagulation factors) 
B) 8% ethanol-precipitation (fraction I) 
C) 25% ethanol supernatant (albumins) 
D) 25% ethanol-precipitation (immunoglobulins) 
E) GCC (negative control) 
At the samples marked with protG (=protein G), the GCC were first labelled with protein G 
and thereafter with the fractions. 
 
fig. 72 Allergy test in vitro with GCC 
For interpretation of an in vitro allergy test, it is important to know the possible cross 
sensitivity of an allergen. An overview about the allergens used in the allergy test and their 
cross reactions is given in (tab. 5) (without demand of completeness). 
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Allergen Cross sensitivity to 
dermatophagoides (mites) crustaceans, sea food 
fungi saccharomyces cerevisiae, penicillin 
mugwort birch tree, ragweed 
ash tree olive, lilac 
birch tree ash tree, mugwort 
short ragweed banana, melon 
grasses cereals, legumes 
cereals grasses 
tab. 5 cross sensitivities 
The GCC solution (1st row and sample E) provide as negative control. HSA-antibody labelled 
GCC (2nd row) was used as positive control reacting with the dotted HSA (10) and shows a 
cross reactivity to the dotted BSA (11). The immunoglobulins after Cohn-fractionation should 
be in the sample D (25% ethanol-precipitation) and the albumins in sample C. 
The patient is allergic to house dust mites (2) (cross sensitivity to other mites (1)), birch tree 
(6) (cross sensitivity to ash tree (5) and mugwort (4)) and grasses (8) (cross sensitivity to 
cereales (9). 
Signals, which agree with the allergy of the patients are visible at sample C with protein G 
and at sample D without protein G. 
The Cohn-fractionation was conducted with only 1 mL of serum, whereby the main problem 
was the age of this serum (older than 10 years) and the half-life of IgE (tab. 3). So much 
better the result of Cohn-fractionation in combination with Gold Cluster Labelling Test. 
To affirm the results, the experiment has to be repeated with a fresh blood withdrawal and the 
results have to be compared with other allergy tests, mainly a skin prick test, to diagnose cross 
sensitivities. 
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Abbreviations 
A  absorbance 
Ab  antibody 
Ag  antigen 
ALP  alkaline phosphatase 
APC  antigen presenting cell 
CBB  Coomassie Brilliant Blue 
CLISA Cluster Linked Immunosorbent Assay 
e.g.  exempli gratia 
DES  drug-eluting stents 
ELISA  Enzyme-Linked ImmunoSorbent Assay 
FIA  fluoro immunoassay 
FG  gelatine from cold water fish skin 
GCC  gold cluster colloid 
H52, H53 rabbits immunised with PLGA-NP 
HRP  horseradish peroxidase 
IA  immunoassay 
Ig  immunoglobulin 
NP  nanoparticle 
o/n  over night 
PAGE  Polyacrylamide Gel Electrophoresis 
PEG  polyethylene glycol 
PLGA  poly(lactic-co-glycolic acid) 
RIA  radio immunoassay 
rt  room temperature 
TCR  T-cell receptor 
w/o/w  water-in-oil-in water 
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Chemicals 
Acetic acid, CH3COOH, MW 60.05, Merck 
Acetone, (CH3)2CO, MW 58.08, J.T.Baker 
Acrylamide/Bis, 30% acrylamide, 0.8% Bis (N,N-methylene bisacrylamide), Sigma 
ALP, Alkaline phosphatase from Bovine Calf Intestine, 0.02 mL, 22 mg protein/mL, 5590 
 units/mg protein, Sigma 
Anti-human-IgG-Peroxidase, SB 2D40-05, #C248-X549J (provided by SCIOTEC) 
Anti-rabbit-IgG-HRP (from unknown origin) 
APS, ammoniumpersulfate, MW 228.2, (NH4)2S2O8, Serva 
APTS, 3-aminopropyltriethoxysilane, C9H23NO3Si, MW 221.37, Fluka 
BCIP, 5-bromo-4-chloro-3-indolyl phosphate, MW 433.62, Pierce 
Bio-Rad Protein Assay, dye reagent concentrate, Bio-Rad Laboratories GmbH 
Bisamino-PEG, O,O´-bis(3-aminopropyl)polyethylene glycol, MW ~1500, Fluka 
Bromophenolblue, indicator pH 3.0-4.6, C19H10Br4O5S, MW 669.99, Merck 
BS3, bis(sulfosuccinimidyl)suberate, MW 572.43, Pierce 
BSA, albumin from bovine serum, Cohn V Fraktion, Sigma 
CBB-R250, Coomassie Brilliant Blue R-250, Serva 
Chloranil, p-Chloranil, C6Cl4O2, MW 245.88, purum ≥ 97.0%, Fluka 
Citric acid-1-hydrat, C6H8O7·H2O, MW 192.12, Riedel de Haën 
Cystamine dihydrochloride, C4H12N2S2·2HCl, MW 225.20, Sigma-Aldrich 
Cysteamine hydrochloride, C2H7NS·Cl, MW 113.61, Fluka 
Disodiumhydrogenphosphate, Na2HPO4, MW 141.96, Riedel de Haën 
1,4-Dioxane, C4H8O2, MW 88.11, Sigma 
DL-α-Lipoic acid, C8H14O2S2, MW 206.33, Fluka 
DTT, 1,4-dithio-D,L-threitol, C4H10O2S2, MW 154.25, Fluka 
EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, MW 191.7, Sigma 
Ellman's Reagent, 5,5´-dithio-bis-(2-nitrobenzoic acid), DTNB, MW 396.4, Pierce 
Ethanol abs., C2H5OH, MW 46.07, Merck 
Ethyl acetate, C4H8O2, MW 88.10, Merck 
Fish gelatine, gelatine from cold water fish skin, Sigma 
Glutaraldehyd e, C5H8O2, MW 100.12, d420 1.063, Fluka  
Glycerin, C3H8O3, MW 92.09, Riedel de Haën  
Glycine, C2H5NO2, MW 75.07, Gerbu 
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Gold(III)chloride trihydrate, HAuCl4·3H2O, MW 393.83, Sigma-Aldrich 
HSA, 96-99%, albumin from human serum, Sigma 
Hycdrochloric acid, HCl, 37-38%, MW 36.46, J.T.Baker 
Hydrogen peroxide, H2O2, MW 34.02, Merck 
Isopropanol, CH3CHOHCH3, MW 60.10, J.T.Baker 
LDH, lactate dehydrogenase, from pig's heart, 5 mg/ml, Roche 
L-LDH , from bovine muscle, 12.6mg protein/ml (Biuret), 643units/mg protein, Sigma 
Magnesium chloride, MgCl2·6H2O, MW 203.30, Sigma-Aldrich 
2-Mercaptoethanol, C2H6OS, MW 78.13, Fluka 
Methanol, CH3OH, MW 32.04, J.T.Baker 
N-Acetyl-L-cysteine, C5H9NO3S, MW 163.19, Sigma 
NADH, β-nicotinamide adenine dinucleotide, reduced form, disodium Salt, C21H27N7O14P2Na2, 
 MW 709.4,  Sigma 
NBT, nitroblue tetrazolium, C40H30N10O6Cl2, MW 817.60, Pierce 
Nitric acid, HNO3, MW 63.01, Merck 
OPA, O-phtaldialdehyde, C6H4(CHO)2, MW 134.14, Fluka 
PageRulerTM, Prestained Protein Ladder, #SM0671, Fermentas 
PLGA, poly(DL-lactide-co-glycolide) (50:50), MW 07462, Fluka 
Pluronic F-68, Sigma 
PonceauS, C22H12N4Na4O13S4, usb 
Protein G´, from Streptococcus sp., recombinant, expressed in E.coli, Sigma   
Pyruvic Acid, C3H4O3Na, Sodium Salt, MW 110.0, Sigma 
SDS, Sodium dodecylsulfate, C12H25O4S·Na, MW 288.4, Serva 
Sodium borohydride, NaBH4, MW 37.83, Aldrich 
Sodium carbonate-decahydrate, Na2CO3·10H2O, MW 286.14, Riedel de Haën 
Sodium chloride, NaCl, MW 58.44, Riedel de Haën 
Sodium dihydrogenphosphate, NaH2PO4, MW 119.98, Riedel de Haën 
Sodium hydrogencarbonate, NaHCO3, MW 84.0, Riedel de Haën 
Sodium hydroxide, NaOH, Merck 
Sodium phosphate, Na3PO4, MW 163.94, Riedel de Haën 
Sodium thiocynate, NaSCN, MW 81.07, Fluka 
Succinic anhydride, C4HO3, MW 100.07, Merck 
Sulfo-NHS, N-hydroxysulfosuccinimide, C4H4NO6SNa, MW 217.14, Pierce 
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Sulfo-SMCC, succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate, MW 334.33, 
 Pierce 
Sulfo-SMPB , Sulfosuccinimidyl-4-(p-maleimidophenyl)butyrate, C18H15N2O9SNa, MW 
 458.36, Pierce 
Sulfuric acid, H2SO4, MW 98.08, Merck 
TEMED, N,N,N′,N′-tetramethylethylenediamine, C6H16N2, MW 116.20, 
TMB, 3,3',5,5'-tetramethylbenzidine, C16H20N2, MW 240.35, SCIOTEC 
TNBS, trinitrobenzene sulfonic acid, 5%(w/v), C6H3N3O9S, MW 293.17, Sigma 
Toluene, C6H5CH3, MW 92,14, Baker 
Tris, Tris(hydroxymethyl)aminomethane, C4H11NO3, MW 121.14, AppliChem 
Trisodiumcitrate-dihydrate, C6H5O7Na3·2H2O, MW 294.10, Riedel de Haën 
TritonX100, 4-(1,1,3,3-tetramethylbutyl)phenyl-polyethylene glycol, Fluka 
Tween20, C58H114O26, MW 1227.72, Sigma 
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